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ABSTRACT 
 
PATRICIA MARIE LENHART: Adrenomedullin and Receptor Activity Modifying Protein 
3 in Women’s Health 
(Under the direction of Kathleen Caron) 
 
Adrenomedullin (AM) is a 52-amino acid peptide vasodilator that is elevated in the 
serum during normal human pregnancies but is often blunted in pregnancy complications 
including preeclampsia. One hallmark feature of preeclampsia is failure of uterine spiral 
arteries to remodel, a process that depends on uterine natural killer (uNK) cells. Our previous 
studies revealed that placentas lacking AM exhibit failed spiral artery remodeling and 
reduced maternal uNK cells. We sought to determine whether there are dosage-related effects 
of AM on the placenta through the use of a mouse model that overexpresses AM (Adm
hi/hi
), 
and found that Adm
hi/hi
 placentas have a significant increase in uNK cell numbers. 
Furthermore, fetal AM dosage alters the immune milieu of the placenta, as numerous 
chemokines and cytokines are oppositely regulated in Adm
hi/hi
 versus Adm
+/-
 placentas. We 
also investigated a variety of single nucleotide polymorphisms in the AM signaling system in 
a human population, and found that several polymorphisms in AM and its signaling 
components are significantly associated with adverse pregnancy outcomes. Together, these 
findings support the central role of AM in human pregnancy and pregnancy complications. 
One component of the AM signaling system is receptor activity modifying protein 3 
(RAMP3), a molecular chaperone known to interact with and affect the trafficking of several 
G protein-coupled receptors (GPCRs). We investigated whether RAMP3 interacts with G 
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protein-coupled receptor 30 (GPR30), a GPCR that binds estradiol and has important roles in 
cardiovascular and endocrine physiology. We found that GPR30 and RAMP3 interact in 
vitro, and the presence of GPR30 leads to increased expression of RAMP3 at the plasma 
membrane. In vivo, there are marked sex differences in the subcellular localization of GPR30 
in cardiac cells, and the hearts of Ramp3
-/- 
mice also show signs of GPR30 mislocalization. 
Next, we treated Ramp3
+/+ 
and Ramp3
-/- 
mice on a heart disease-prone genetic background 
with a specific agonist for GPR30. Importantly, activation of GPR30 resulted in a significant 
reduction in cardiac hypertrophy and perivascular fibrosis that is both RAMP3- and sex-
dependent. Thus, the GPR30-RAMP3 interaction has functional consequences on the 
localization of these proteins and RAMP3 is required for GPR30-mediated cardioprotection. 
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Chapter 1: Adrenomedullin and Pregnancy: Perspectives from Animal Models to 
Humans
1,2
 
 
Overview 
A healthy pregnancy requires strict coordination of genetic, physiologic, and 
environmental factors. The relatively common incidence of infertility and pregnancy 
complications has resulted in increased interest in understanding the mechanisms that 
underlie normal versus abnormal pregnancy. The peptide hormone adrenomedullin (AM) has 
recently been the focus of some exciting breakthroughs in the pregnancy field. Supported by 
mechanistic studies in genetic animal models, there continues to be a growing body of 
evidence demonstrating the importance of AM protein levels in a variety of human 
pregnancy complications. With more extensive mechanistic studies and improved 
consistency in clinical measurements of AM, there is great potential for the development of 
AM as a clinically-relevant biomarker in pregnancy and pregnancy complications. 
  
The Calcitonin Gene-Related Peptide (CGRP) Family 
There are a multitude of genetic, physiologic, and environmental factors that must all 
work in perfect harmony throughout pregnancy to produce the so-called ‘‘miracle’’ that is a 
healthy full-term baby. Any aberration in this process may result in pregnancy complications, 
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which can include implantation failure, miscarriage, fetal growth restriction, gestational 
diabetes, preeclampsia (PE), and preterm birth. Given this complexity, there is currently a 
major interest and effort in the field to expand our understanding of the factors that 
contribute to healthy versus unhealthy pregnancies. 
One of these active areas of study is the CGRP family and the critical roles these 
peptides play in female reproductive biology. The CGRP family is composed of five known 
peptides, CGRP, adrenomedullin (AM), calcitonin (CT), amylin (AMY), and 
intermedin/adrenomedullin 2 (IMD), that share a similar molecular structure and overlapping 
biological functions. The critical role of the CGRP family in sustaining life is suggested by 
the fact that these peptides are highly conserved throughout vertebrate evolution, with CGRP 
family genes dating as far back as the evolutionarily-distant teleost fish species [2]. The 
peptides of this family have little sequence homology but share similar secondary structures 
consisting of an amino acid ring structure formed by a single disulfide bond and a carboxyl 
terminus amidation [3-5]. CGRP family peptides are widely expressed in both peripheral 
tissues and the central nervous system and they are involved in diverse physiological 
functions, including vasodilation (AM, CGRP, IMD), angiogenesis (AM, CGRP), pain 
perception (CGRP), glucose metabolism (AMY), and bone mineral metabolism (CT) [6]. In 
addition to these previously known roles, emerging research implicates the CGRP family as 
having multiple essential roles in the establishment and maintenance of the healthy 
pregnancy. This review will focus on the CGRP family member AM and the many well-
characterized and emerging roles it has in reproduction.  
AM was first identified in 1993 from human pheochromocytoma tissue extracts and is 
perhaps best known for its potent vasodilatory action [7]. The AM signaling paradigm is a 
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unique one, in which AM binds its G protein-coupled receptor, calcitonin receptor-like 
receptor (CLR), when the receptor is associated with receptor activity modifying protein 2 or 
3 (RAMP2 or 3). The RAMPs dictate ligand binding specificity, therefore when CLR 
associates with RAMP1 this complex forms a receptor for the peptide CGRP rather than AM 
[8]. Other CGRP family members utilize different receptor and RAMP combinations. CT 
binds the calcitonin receptor without a RAMP present, but when RAMPs1, 2, or 3 associate 
with the calcitonin receptor it forms a receptor for AMY [3]. The receptor for IMD is not 
well characterized and is perhaps as yet unknown. This signaling paradigm adds a layer of 
complexity to interpreting experimental findings related to AM. The fact that CLR binds both 
CGRP and AM as ligands means that changes in CLR cannot always be extrapolated to 
indicate changes in AM signaling. Similarly, the RAMP family members interact with other 
receptors besides CLR [9] so RAMP alterations are also not necessarily AM-specific. AM 
signaling has been implicated in biological functions including cellular growth, regulation of 
blood pressure, protection from vascular hypertrophy and inflammation, inhibition of left 
ventricular hypertrophy and remodeling, stimulation of diuresis and natriuresis, and 
promotion of angiogenesis and lymphangiogenesis [10]. However, recent studies using 
genetic animal models add complimentary evidence of roles for AM in reproductive biology. 
 
AM and Normal Pregnancy  
 
Expression of AM 
AM and its receptor components are highly expressed in reproductive tissues, 
including the uterine endometrium [11], fetal membranes [12], placenta [13], endometrial 
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stromal macrophages [14], and trophoblast cells [15-18]. AM expression is regulated by 
multiple factors involved in the physiology of reproduction. Hypoxia, via hypoxia inducible 
factor 1 alpha (HIF-1α), potently upregulates AM expression in multiple tissue types in 
culture, including placental cytotrophoblast cells [19-21]. The regulation of AM by HIF-1α 
in hypoxia is of particular relevance to pregnancy because physiological hypoxia in the first 
trimester placenta is essential for normal trophoblast invasion and proper placental and 
embryonic development [22]. By contrast, the low oxygen tension that is necessary for first 
trimester development would be considered pathological in later pregnancy, and late 
pregnancy hypoxia is associated with complications including PE and intrauterine growth 
restriction (IUGR) [23]. Therefore, it is likely that both normal and abnormal levels of 
oxygen tension during pregnancy directly contribute to the expression and secretion of AM 
from reproductive tissues. However, the downstream physiological effects of hypoxia-
induced AM expression in placental tissues have yet to be resolved.  
Figure 1-1 summarizes the pattern of AM expression in multiple stages of pregnancy. 
Watanabe et al. administered estrogen to mice and found that with estrogen treatment AM 
and one of its receptor components, RAMP3, are transcriptionally upregulated in the 
endometrial stroma by estrogen receptor alpha (ERα) (Figure 1-1a) [24]. ERα is expressed in 
the blastocyst trophectoderm and the uterine luminal epithelium in the peri-implantation 
period [25,26]. Estradiol levels reach their peak at ovulation, which prepares the uterus for 
implantation by stimulating cellular proliferation and differentiation of the luminal and 
glandular epithelium, and by induction of progesterone receptor expression in the 
endometrial stroma and myometrium. This process, as well as the upregulation of AM and 
RAMP3 gene expression, fails in mice lacking ERα, resulting in implantation failure and 
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infertility [26]. By genome-wide microarray analysis, RAMP3 was identified as one of the 
most potently estrogen-induced genes in the uterus [27]; thus, it is likely that AM signaling 
through a CLR/RAMP3 complex plays an important function in regulating some of the 
estrogenic effects of uterine receptivity and implantation. 
The dynamic regulation of AM expression in female reproductive tissues results in 
significant changes in plasma AM levels during the course of human gestation. During 
normal pregnancy, plasma AM concentration increases steadily, reaching levels four to five 
times higher than the pre-pregnancy state by the third trimester [13,28-32]. Plasma AM 
levels rapidly drop back to pre-pregnancy values within 24 hours after delivery [13], which 
supports the notion that maternal plasma AM is derived largely from the placenta. 
 
AM in fertility and implantation  
An important role of AM in fertility and implantation has come from well 
characterized animal models. Recent findings have implicated AM in even the earliest stages 
of pregnancy. Li et al. showed that in a rat model, ovarian AM expression increases from 
small antral follicles to large antral follicles to the formation of the corpus luteum, and AM 
appears to be involved in the regulation of progesterone production from the corpus luteum 
[33]. AM also increases ciliary beat frequency and reduces contraction in the rat oviduct, 
pointing to a role for AM-mediated regulation of embryo transport to the uterus [34]. 
Expression of AM and its receptor components are induced in the luminal epithelium of the 
murine uterus as early as pregnancy day 0.5. By the peri-implantation period, AM is 
expressed both by the blastocyst trophectoderm and the uterine luminal epithelium and 
6 
 
stroma at the implantation site (Figure 1-1A,B) [35]. Therefore, the peptide is abundantly 
expressed throughout the female reproductive tract from the earliest stages of pregnancy.  
Homozygous deletion of Adm results in embryonic lethality with abnormal 
development of the heart and lymphatic vascular system [36]. However, female mice 
heterozygous for Adm (50% AM expression) survive and are a very useful model for the 
study of haploinsufficiency of AM during pregnancy. Adm
+/-
 female mice have a significantly 
reduced pregnancy success rate compared with wildtype females, despite the fact that 
ovulation and fertilization occurs normally in these mice. This reduced pregnancy rate 
persists even when wildtype blastocysts are transferred to the Adm
+/-
 female, indicating that 
reduced maternal AM is responsible for the uterine receptivity defects in this model [37].  
Furthermore, Adm
+/-
 female mice have reduced numbers of uterine pinopodes 
(referred to as uterodomes in humans), which are plasma membrane extravasations of the 
uterine luminal epithelium that faithfully mark the window of uterine receptivity [35]. Even 
when implantation is successful in the Adm
+/-
 female, fertility defects persist. The litter sizes 
of Adm
+/-
 female mice are reduced when mated with wildtype males, whereas normal litter 
sizes are born to wildtype females mated with Adm
+/-
 males. The implantation sites in 
pregnant Adm
+/-
 females are abnormally spaced and overcrowded, resulting in increased rates 
of embryo loss and remarkable subfertility [37]. Therefore, even a modest 50% reduction in 
maternal expression of AM is sufficient to cause major implantation and fertility 
complications in genetic mouse models. 
This strong genetic and physiological evidence from rodent models is beginning to be 
translated to clinical medicine as well. For example, Marinoni et al. have recently found that 
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elevated AM levels in follicular fluid is associated with negative outcomes in in vitro 
fertilization patients [38]. 
 
AM in placentation and maternal–fetal circulation 
One of the most essential maternal responses to pregnancy is the vascular remodeling 
of uterine spiral arteries, which ensures adequate blood flow to the developing fetus. The 
development of the placenta is central to this process. The earliest stages of placental 
development in humans and rodents occur during implantation, when trophectoderm cells 
from the blastocyst attach and invade into the wall of the receptive uterus. These 
trophectoderm cells differentiate into multinucleate trophoblast cells termed extravillous 
cytotrophoblasts in humans and giant trophoblast cells in rats and mice, which invade the 
uterine lining and establish the vascular connection between fetal placental tissue and the 
maternal blood supply [39]. High AM expression is present in the trophectoderm cells and 
persists in trophoblast giant cells in the mouse [18,37] whereas AM expression in the 
extravillous cytotrophoblast lineage has been shown in the normal term placenta in humans 
(Figure 1-1C) [15,16,40]. Support for a role for AM in trophoblast invasion has come from in 
vitro studies. Zhang et al. showed that AM induces proliferation and invasion in JAr cells, a 
choriocarcinoma cell line, and in HTR-8/SV neo cells, a first trimester cytotrophoblast cell 
line [41]. In isolated fetoplacental vascular beds and stem villous arteries previously 
constricted with a thromboxane sympathomimetic, AM infusion induces a dose-dependent 
vasodilation, suggesting that AM may help maintain low placental vascular resistance 
[42,43]. Recently, Ross et al. found that AM treatment in rats induces relaxation of the 
uterine artery and this effect is enhanced in pregnancy or with estradiol treatment, providing 
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further evidence for a functional role for AM in maintaining vascular tone in pregnancy [44]. 
In women with unexplained recurrent pregnancy loss, high plasma AM was associated with 
increased uterine artery pulsatility index and an increased number of previous miscarriages, 
from which the authors suggest that increased AM may be acting in a compensatory role 
[45]. 
 
AM in Pregnancy Complications 
Defects in the ability of trophectoderm cells to fully invade the maternal uterine wall 
and remodel vessels are thought to underlie many serious reproductive conditions [46,47]. 
Given that female mice heterozygous for Adm exhibit marked subfertility, and that 
homozygous deletion of Adm causes embryonic lethality, it is not surprising that altered AM 
expression has been associated with several of these pregnancy complications. Table 1-1 
summarizes many of the clinical studies that have measured AM in pregnancy complications. 
 
IUGR  
Numerous rodent models have provided evidence for the necessity of AM in normal 
fetal growth. Yallampalli’s laboratory found that antagonism of AM during pregnancy 
resulted in IUGR, abnormal placental vascularization and increased fetal resorption in the rat 
[48,49]. Similar studies in the mouse have shown that Adm
+/-
 mothers have a high rate of 
fetal growth restriction, which occurs in all fetal genotypes. The incidence of fetal growth 
restriction was highest among Adm
-/-
 embryos, indicating that both maternal and fetal AM 
may contribute to normal fetal growth [37]. 
Results from human studies have not been as consistent. Two early studies found that 
elevated AM levels in the umbilical plasma and amniotic fluid, respectively, were associated 
9 
 
with reduced fetal growth [50,51], which could be a compensatory effect. However, a 2001 
study by Yamashiro et al. and a more recent study by Akturk et al. showed no difference in 
AM concentrations between small for gestational age and appropriate for gestational age 
infants [52,53]. Based on animal studies, it is likely that altered AM levels may contribute to 
either the development of IUGR or the resulting adaptive compensation to other primary 
causes of IUGR. However, the inconsistencies between studies in the human population 
points to the necessity of further studies to determine with certainty how changes in AM 
levels may be involved in the pathogenesis of growth-restricted pregnancies. 
 
AM in gestational diabetes  
To date, there is relatively limited data available on whether AM levels are altered in 
gestational diabetes. Martinez et al. showed no change in plasma AM levels in pregnant 
women with gestational diabetes compared to pregnant women without gestational diabetes 
[54]. Di Iorio et al. also found that AM levels were not changed in the maternal circulation, 
but found higher AM levels in the amniotic fluid of pregnant diabetic women [55]. Plasma 
AM was found to be unchanged in pregnant women with type I diabetes mellitus (T1DM) 
[56], and in a subsequent study AM was found to be unchanged in the plasma of women with 
gestational diabetes [57]. These data suggest that circulating AM may not be altered in 
pregnant women with gestational diabetes, but fetal or placental AM production may be 
elevated, potentially resulting in the observed increased amniotic fluid AM concentration. 
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AM in PE 
Based on the known roles for AM in trophoblast invasion and vascular adaptation to 
pregnancy, there is significant interest in determining whether changes in AM peptide or 
expression levels contributes to the pathogenesis of PE. Results from an experimental rat 
model of maternal hypertension further piqued this interest. In this model, whereby 
administration of the inhibitor of nitric oxide synthases, L-NAME (nitro-L-arginine methyl 
ester), during gestation results in hypertension and pup mortality; maternal infusion of AM 
attenuated the hypertensive phenotype [58].  
However, results from human studies have been highly variable and controversial. 
One of the earliest studies examining AM levels in PE, by Hata et al., found that circulating 
AM levels were reduced in women with PE [59]. A multitude of other studies have found 
markedly variable results. For example, studies have shown either decreased [60-62] or 
increased [15] AM mRNA levels in placental tissues of preeclamptic patients. Attempts to 
look at AM protein levels have been equally variable. AM peptide production from purified 
cytotrophoblast cultures of preeclamptic patients was shown to be decreased [63], and the 
majority of studies looking at plasma levels of AM have been inconsistent, showing both 
increased [32,64-66], decreased [67], and unchanged [13,43] AM levels in PE. Al Ghafra et 
al. attempted to clarify the role of AM in PE by limiting their study to patients with severe 
PE and by separating patients by term versus preterm delivery; they found that AM protein 
levels were increased in fetal membranes in PE patients with both term and preterm 
gestation, and AM mRNA levels were also increased in preterm choriodecidual tissue in PE 
patients [68]. Although there is strong evidence for altered AM levels being either a cause or 
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a secondary effect in PE, it is clear that more controlled experiments to address the direction 
of the change and the exact role of AM in PE are needed. 
 
AM and preterm birth  
It has long been thought that altered AM levels may be present in cases of preterm 
birth. Human studies dating back over 10 years ago have suggested that AM protein may be 
elevated in patients with preterm birth. The Di Iorio laboratory has published several studies 
on this subject, finding increased amniotic AM levels in cases of preterm premature rupture 
of membranes (PPROM) [69], and increased amniotic fluid AM in patients with preterm 
labor [70]. Elevated second trimester amniotic fluid levels of AM have also been reported in 
patients that go on to preterm deliveries [51]. Glucocorticoids may be involved in the 
regulation of AM levels in pregnancy, as administration of betamethasone to stimulate fetal 
lung maturity in patients at risk for preterm birth resulted in significantly increased maternal 
and fetal plasma AM levels [71]. However, a 2009 study by Iavazzo et al. found that there 
was no change in AM levels in spontaneous preterm delivery or PPROM [72], suggesting 
that further studies may still be needed in this area. 
In addition to genetic and environmental causes, it is interesting to speculate as to 
whether AM may play a role in another major cause of preterm birth – ascending intra-
uterine bacterial infections, which are thought to account for 25–40% of preterm births [73]. 
The spread of microorganisms to the amniotic cavity causes the activation of toll-like 
receptors and the release of proinflammatory cytokines, leading to increased prostaglandins 
and the stimulation of premature uterine contractions and degradation of fetal membranes 
[74,75]. There are multiple characteristics of AM that implicate it as a regulator of innate 
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immunity and host defense [76]. These include its six-member cysteine ring structure, 
characteristic of both human and murine beta-defensins [77] which allows these molecules to 
penetrate bacterial cell membranes, and the known anti-inflammatory effects of AM [78]. 
The potent bactericidal properties of AM [79] and its high level of expression in the skin, 
oral cavity cervical mucosa, fetal membranes, and breast milk [12,80] also support its role as 
a possible mediator of host defense. Future studies exploring a potential role for AM in 
providing antimicrobial effects in relation to preterm birth have the potential to be highly 
informative. 
 
Caveats to current AM detection methods and midregional fragment of pro-adrenomedullin 
(MR-proADM)  
The broad expression pattern of AM, its variety of biological activities during 
pregnancy and the variation in clinical criteria between studies are complicating factors that 
may be responsible for some of the inconsistencies in characterizing AM levels in abnormal 
pregnancies (Table 1-1). However, the assay systems used to measure AM are also probably 
culprits in this controversy. The accurate measurement of AM is technically challenging 
owing in large part to the short half-life of AM peptide (22 min) [81], and that it is highly 
unstable and ‘sticky’. Issues regarding antibody specificity and species differences in 
detection methods can also be confounding factors. However, the precursor prohormone to 
AM, MR-proADM, has been identified as a stable circulating peptide [82]. MR-proADM is 
an excellent proxy for measuring AM levels because it is highly stable in contrast to the 
mature form of AM [83]. Measurement of MR-proADM via a sandwich fluoroimmunoassay 
has been described [83,84] and has been used to measure AM in patients with sepsis [85], 
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community acquired pneumonia [86], and heart failure [87,88], and demonstrates excellent 
clinical utility for MR-proADM as a diagnostic and prognostic biomarker. 
Application of this new assay has been limited in the reproductive and pregnancy 
field so far, but to date two groups have measured MR-proADM levels in neonates. Miguel 
et al. established reference values for MR-proADM in umbilical cord blood of newborn 
infants [89], whereas Cao et al. found that serum levels of MR-proADM were significantly 
elevated by more than twofold in newborns with severe infection compared to those with 
mild or no infection [90]. Although this study was performed in newborns, it provides an 
interesting correlation with the hypothesis that AM may act as a regulator in host defense 
preventing infections during pregnancy, and suggests that this AM precursor could 
potentially be used as a laboratory marker of bacterial infection in neonates. Further studies 
utilizing the MR-proADM assay in the study of pregnancy have the potential to yield newly 
accurate and exciting results, improving our understanding of how AM levels change in 
healthy versus complicated pregnancies in humans and perhaps even validating MR-
proADM as a potential biomarker for pregnancy-related diseases.  
 
AM system polymorphisms  
Although the intriguing results from human studies characterizing AM levels in 
pregnancy conditions are still relatively inconclusive when taken together, the potential 
clinical significance of altered levels of AM and its receptor components is bolstered by the 
discovery of polymorphisms in the human AM system genes. Figure 1-2 depicts the structure 
of the ADM gene and the location of clinically-relevant polymorphisms. The ADM gene is 
flanked by a 3’ microsatellite cytosine adenine (CA) repeat region, and in a Japanese patient 
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population, an ADM allele with 19 CA repeats was found with significantly increased 
frequency in individuals with essential hypertension (EH) compared to normotensive controls 
[91]. This same polymorphism has been associated with predisposition to proteinuria in EH 
and is found with greater frequency in type II diabetic patients in renal failure compared to 
controls or diabetic patients without nephropathy [92,93]. Specific single nucleotide 
polymorphisms (SNPs) in AM have also been associated with reduced systolic blood 
pressure, lower pulse pressure, and reduced urinary sodium excretion in a Chinese population 
[94], increased risk of developing dysglycemia in a Chinese population [95], and altered 
response to the antidepressant paroxetine [96]. A particular SNP in the AM receptor gene, 
CALCRL, was found with increased frequency specifically among women with EH in a 
Japanese population [97], and other studies have found CALCRL SNPs associated with 
severe periodontitis [98] and acute primary angle closure glaucoma [99]. Recently, different 
ADM haplotypes have been shown to correlate with changes in plasma AM levels [100], 
making the connection between polymorphisms in the ADM gene and level of expression. 
With relation to the important role of AM signaling in female reproduction, a study 
by Wang et al. tested SNPs from 41 genes associated with fetal growth. Interestingly, a SNP 
in the AM receptor CALCRL was one of just six SNPs in five genes that were significantly 
associated with birth weight in a population of African-American women [101], indicating 
that CLR levels (and by extension, AM signaling) may be important for fetal growth in 
human subjects. Boc-Zalewska et al. have now shown that ADM gene polymorphisms are 
associated with changes in AM mRNA expression and increased incidence of gestational 
hypertension and PE [62,66], providing additional evidence for a role for AM in the 
pathogenesis of this condition. Further characterization of ADM polymorphisms and whether 
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they are associated with pregnancy complications is an emerging translational research target 
with great potential. 
 
Concluding Remarks 
The importance of CGRP family peptide AM in the establishment and maintenance of 
the healthy pregnancy is clearly supported by many studies spanning the past 15 years. Our 
understanding of the functions of AM in normal and in complicated pregnancies has 
advanced significantly in the past 5 years largely as a result of studies using genetic animal 
models. However, unanswered questions remain (Figure 1-3). Inconsistent results from 
human studies attempting to characterize changes in AM levels in pregnancy-related diseases 
have left us with few definitive conclusions. A newly available method to detect AM with 
accuracy holds great promise in clarifying these variable findings. Furthermore, additional in 
vitro and in vivo methods should be employed to gain a greater understanding of the 
mechanisms by which AM mediates its effects in reproductive biology, with the intention of 
linking the biological functions of the peptide to physiologically-relevant paradigms such as 
host defense, vasodilation, angiogenesis, or regulation of innate immunity. Although there is 
still much to learn, given the essential roles of AM in reproduction, there is potential for the 
development of AM as a clinically-relevant biomarker in pregnancy and pregnancy 
complications. 
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TABLES 
Table 1-1: Adrenomedullin levels in pregnancy complications 
Pregnancy 
Complication 
Sample 
Source 
Sample 
Type 
Assay 
Change in AM 
Levels 
Ref 
IUGR 
umbilical 
plasma 
AM 
protein 
commercial RIA ↑ 1.67X in IUGR 50 
IUGR 
maternal and 
cord venous 
blood 
AM 
protein 
"non-commercial" 
RIA 
No change 53 
Reduced Fetal 
Growth 
amniotic fluid 
AM 
protein 
"non-commercial" 
RIA 
AM levels inversely 
correlate with birth 
weight and height 
51 
IUGR 
umbilical  and 
maternal 
plasma 
AM 
protein 
HPLC No change 52 
Gestational 
Diabetes 
maternal 
plasma 
AM 
protein 
commercial RIA No change 54 
Gestational 
Diabetes and 
Pregnant 
Women with 
T1DM 
maternal and 
fetal plasma, 
amniotic fluid 
AM 
protein 
commercial RIA 
↑ 1.36X in amniotic 
fluid of diabetic 
pregnancies; no 
change in maternal 
or fetal plasma 
55 
Pregnant 
Women with 
T1DM 
maternal 
plasma 
AM 
protein 
"non-commercial" 
RIA 
No  change 56 
Gestational 
Diabetes 
maternal 
plasma 
AM 
protein 
"non-commercial" 
RIA 
No  change 57 
PE 
maternal 
plasma 
AM 
protein 
commercial RIA ↓1.35X in PE 59 
PE 
amniotic fluid, 
maternal and 
umbilical 
plasma 
AM 
protein 
commercial RIA 
↑2.25X in amniotic 
fluid and ↑2.13X in 
umbilical plasma in 
PE; no change in 
maternal plasma 
64 
PE 
maternal 
plasma 
AM 
protein 
"non-commercial" 
RIA 
No  change 13 
PE 
maternal 
plasma 
AM 
protein 
commercial RIA ↑2.5X in PE 65 
PE 
maternal 
plasma 
AM 
protein 
"non-commercial" 
RIA 
No  change 43 
PE placental villi 
AM 
mRNA 
qRT-PCR 
↓1.83X expression 
in PE 
61 
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PE 
purified 
cytotrophoblast 
cultures 
AM 
protein,  
mRNA 
commercial RIA, 
Northern blot 
↓2.91X mRNA and 
↓5X protein in PE 
63 
PE 
choriodecidua, 
amnion, and 
placental tissue 
AM 
protein, 
mRNA 
commercial RIA, 
Northern blot 
↑1.66-2.9X in 
choriodecidua, 
↑1.63-2.26X in 
amnion; no  change 
in placental tissue 
68 
PE 
maternal 
plasma 
AM 
protein 
ELISA ↑1.3X in PE 32 
PE 
maternal 
plasma 
AM 
protein 
HPLC ↓1.92X in PE 67 
PE placental tissue 
AM 
mRNA 
qRT-PCR 
↓1.18X mRNA in 
PE 
62 
PE 
maternal 
plasma 
AM 
protein 
ELISA ↑1.07X in PE 66 
Preterm Labor 
/ Premature 
Rupture of 
Membranes 
amniotic fluid 
AM 
protein 
commercial RIA ↑1.75X in PROM 69 
Preterm Labor 
maternal and 
fetal plasma, 
amniotic fluid 
AM 
protein 
commercial RIA 
↑2.95X in amniotic 
fluid in preterm 
labor; no change in 
maternal or fetal 
plasma 
70 
Preterm 
Delivery 
amniotic fluid 
AM 
protein 
"non-commercial" 
RIA 
↑ 1.40X in preterm 
delivery 
51 
Preterm Labor amniotic fluid 
AM 
protein 
ELISA No  change 72 
IUGR = Intrauterine Growth Restriction, PE = Preeclampsia, RIA= radioimmunoassay, 
T1DM = type 1 diabetes mellitus, qRT-PCR = Real-Time Quantitative Reverse Transcription 
PCR, ELISA = Enzyme-linked immunosorbent assay, HPLC = High-performance liquid 
chromatography 
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FIGURES 
 
Figure 1-1. Adrenomedullin expression during pregnancy 
Adrenomedullin (AM) expression in multiple stages of pregnancy. A. AM expression is 
regulated by estrogen (E2), progesterone and hypoxia inducible factor 1 alpha (HIF-1α). At 
the pre-implantation stage, AM is expressed by both the trophectoderm cells and the luminal 
epithelium, promoting uterine receptivity. The maternal components are colored blue and red 
whereas the fetal components are depicted in green and gray. B. At the site of implantation, 
AM continues to be expressed from the trophectoderm cells and from the luminal epithelium, 
which is important for successful implantation. C. In the developed placenta, AM is most 
highly expressed by trophoblast giant cells (mice) or extravillous cytotrophoblasts (humans) 
and may contribute to the maintenance of placental vascular tone. For both B and C, 
maternal components are colored blue and red and the fetal components are depicted in green 
and yellow.   
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Figure 1-2. Clinically-relevant adrenomedullin (AM) polymorphisms 
The structure of the ADM gene and the location of clinically-relevant ADM polymorphisms 
are shown. The dark green box represents AM, light green represents proAM, the 
prohormone for both AM and proadrenomedullin N-terminal 20 peptide (PAMP), and blue 
represents noncoding regions of the ADM gene. Polymorphisms in ADM have been 
associated with changes in plasma AM levels, drug responses, blood pressure, proteinuria, 
renal disease, dysglycemia, and preeclampsia (PE). 
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Figure 1-3. Outstanding questions about the role of adrenomedullin in pregnancy 
Unanswered questions remain regarding the function and clinical relevance of 
adrenomedullin in pregnancy. 
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Chapter 2: Adrenomedullin, Pregnancy, and Innate Immunity
3,4
 
 
Introduction 
As discussed in the previous chapter, adrenomedullin (gene=Adm, peptide=AM) is 
important for the establishment and maintenance of a healthy pregnancy, and aberrant AM 
levels are associated with numerous pregnancy complications [2]. One such pregnancy 
complication in which altered AM levels are implicated is preeclampsia. Clinical 
manifestations of preeclampsia include gestational hypertension, proteinuria, systemic 
endothelial dysfunction, and an exaggerated immune response [3,4]. Causative factors for the 
development of preeclampsia are not well understood, but it is clear that the placenta plays a 
central role. The clinical symptoms of preeclampsia are resolved with childbirth; however, a 
consequence of premature induction of labor for the treatment of preeclampsia is the 
undesirable prematurity of the infant, which can increase the risk of life-long sequelae and 
health complications for the child.  
A hallmark pathological (and perhaps causative) feature of preeclampsia is the failure 
of the maternal spiral arteries of the placenta to remodel during midgestation [5-7]. During a 
normal pregnancy, maternal uterine spiral arteries must undergo a complex restructuring in 
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order to ensure a low-resistance, non-pulsatile flow of blood to the fetus.  The remodeling is 
a complex event that involves several distinct processes: i) endothelial cell vacuolization and 
relaxation of vascular smooth muscle cells (VSMCs) leading to arterial dilation and growth, 
ii) induction of local placental factors including matrix metalloproteinases (MMPs), 
chemokines, and cytokines which in turn cause iii) dissolution of the extracellular matrix, iv) 
de-differentiation and apoptosis of VSMCs and v) replacement of VSMCs by invasive fetal 
trophoblast cells [8-12]. 
It is widely accepted that fetal trophoblast cells, in coordination with maternal uterine 
natural killer (uNK) cells, orchestrate the dynamic process of spiral artery remodeling.  uNK 
cells are the most abundant of all decidual leukocytes, accounting for approximately 70% of 
CD45-positive cells, and are histologically identified by large cytoplasmic granules 
containing perforin and granzymes [8]. uNK cells, which are transiently present in the 
decidua, are frequently aggregated around spiral arteries and play a functional role in 
remodeling [13-15]. Pioneering studies by Anne Croy and colleagues have demonstrated that 
the spiral arteries of transgenic mice that lack uNK cells show a persistence of VSMCs 
surrounding undilated spiral arteries [8,16,17]. Importantly, uNK cells secrete a wide variety 
of growth factors, chemokines, cytokines, and matrix metalloproteinases [11] and thus are 
major contributors to the immune milieu of the placenta. However, much remains unknown 
about the precise molecular interactions between fetal trophoblast cells and uNK cells in the 
placenta. It is also unclear whether perturbations in this fetal-to-maternal communication can 
account for failed spiral artery remodeling and preeclampsia. 
Based on the Caron Laboratory’s long-standing interest in AM as an essential factor 
in female reproduction, we have hypothesized that AM may be involved in the fetal-maternal 
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communication required for proper spiral artery remodeling and the prevention of 
preeclampsia. To test this hypothesis, previous work in the Caron Laboratory focused on 
characterizing the placentas of Adm
+/+
 and Adm
-/-
 pups at midgestation to determine the 
consequences of the loss of AM on placental morphology and function. These studies 
revealed that placentas lacking either AM or its receptor, CLR, exhibit reduced fetal vessel 
branching in the labyrinth, failed spiral artery remodeling and re-endothelialization, and 
marked reduction in maternal uNK cells [1]. Based on these findings, we sought to determine 
whether there are dosage-related effects of AM on the placenta, which we investigated 
through the use of a mouse model that overexpresses AM (Adm
hi/hi
). We also characterized 
the chemokine and cytokine profile of both Adm
-/-
 and Adm
hi/hi
 placentas, to determine 
whether AM dosage, via uNK cells, alters the immune milieu of the placenta. 
 
Materials & Methods 
 
Mice 
Generation of mice with a targeted, homozygous deletion of the Adm gene has been 
previously described [18]. These mice are maintained on an isogenic 129S6/SvEv 
background. Adm
hi/hi 
mice were generated by standard gene targeting protocols. The 
endogenous 3’ untranslated region (UTR) of the Adm gene was replaced with a cassette 
containing the bovine growth hormone UTR as previously described [1]. For timed 
pregnancies, heterozygous male and female Adm
+/– 
or Adm
+/hi
 intercrosses were established, 
and the day when the vaginal plug was detected was considered embryonic day 0.5 (e0.5). 
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Fetal genotypes were determined by established allele-specific, PCR-based assays [1,18] 
using genomic DNA isolated from fetal membranes or tail biopsies. 
 
Cytokine expression arrays 
RNA was extracted from whole placentas using Trizol reagent (Invitrogen 15596-
026) and purified with Qiagen RNeasy Mini Kit (Qiagen 74104). cDNA was made using the 
RT First Strand Kit (SABiosciences C-03) and cytokine expression was determined utilizing 
RT
2
 Profiler PCR Array System for Mouse Chemokines and Receptors (SABiosciences, 
PAMM-022A-2) with PCR Master Mix RT
2
 Real-Time SYBR Green/ROX (SABiosciences 
PA-012) following the manufacturer’s instructions. Data was analyzed using the ΔΔCt 
method. 
 
Immunohistochemical antibodies 
Anti- smooth muscle actin antibody (Sigma, A2547), anti-perforin antibody (Alexis 
Biochemicals, 804-057-C100), Ly49G2+ (BD Pharmingen, 55-5314), FITC-conjugated 
Dolichos biflorus agglutinin (DBA) lectin (Sigma, L9142). 
 
Results 
 
Over-expression of fetal Adm reverses the placental phenotype and drives maternal uNK cell 
recruitment to the decidua 
The finding of reduced uNK cell numbers in Adm
-/-
 placentas suggested that there 
may be abnormalities in their recruitment to the tissue. To determine whether fetal AM can 
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directly influence the recruitment of uNK cells to the decidua, we utilized a gene-targeted 
mouse model in which the expression of AM is increased ~3-fold [1].  
Placentas of Adm
hi/hi
 pups born to Adm
+/hi 
intercrossed mice appeared overtly normal 
and had appropriately branched labyrinth fetal vessels that were indistinguishable from their 
wildtype littermates [1]. Moreover, α-smooth muscle actin staining revealed that the maternal 
spiral arteries of Adm
hi/hi
 placentas were appropriately remodeled and did not differ 
significantly from those of wildtype littermates (Figure 2-1A). Interestingly, DBA staining 
(Figure 2-1B) and counting (Figure 2-1C) of uNK cells revealed that Adm
hi/hi
 placentas had a 
marked 30% increase in the number of uNK cells within the decidua compared to that of 
wildtype littermates. These data demonstrate that 3-fold overexpression of Adm is compatible 
with normal placental development and moreover, that fetal-derived AM can actively 
promote the recruitment of uNK cells to the placenta. 
 
AM alters the chemokine/cytokine profile of uNK cells in vivo 
 uNK cells constitute the largest proportion of immune cells in the decidua. Thus, we 
expected and found that the dynamic fluctuations in uNK cell recruitment between Adm
-/-
 and 
Adm
hi/hi
 placentas were reflected by concomitant changes in the expression of numerous 
chemokines and cytokines. Specifically, the expression of Ccl7, Ccl17, Cxcl9, Cxcl10, Xcl1 
and TNF were down-regulated in Adm
-/-
 placentas and concomitantly up-regulated in Adm
hi/hi
 
placentas, compared to their respective wildtype controls (Figure 2-2). Other studies in the 
Caron Laboratory have shown that treatment of isolated uNK cells with AM stimulates the 
release of various cytokines and chemokines and increased expression and activity of matrix 
metalloproteinase 9 [1]. Collectively, these data demonstrate that fetal-derived AM potently 
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influences the immune milieu of the placenta in two ways—by first recruiting and then 
activating uNK cells to secrete chemokines, cytokines, and MMPs, which are important 
contributors to spiral artery remodeling. 
 
Discussion 
 These data are part of a larger study showing, through the use of both loss-of-function 
and gain-of-function genetic mouse models, that fetal AM serves as a trophoblast-derived 
factor that is critical for fetal placental vascularization and for the maternal vascular 
adaptation to pregnancy (modeled in Figure 2-3). Ultimately, the mechanisms of AM action 
appear to be largely mediated through its local effects on the decidual content and activation 
of maternal uNK cells. Therefore, the phenotypes associated with Adm
-/-
 placentas and their 
reversal by Adm overexpression demonstrate that the dosage of AM provided by the fetus is a 
critical communication factor that has a profound impact on the innate immune milieu of the 
placenta. 
 It is worth noting that nearly all of the characteristic features of the Adm
-/-
 placentas 
are similar to the pathological features which have been characterized in human 
preeclampsia. Although it is imperative to consider the anatomical and functional differences 
between placentas of humans and mice [19-21], the reduction in fetal vascular branching, 
failed spiral artery remodeling, and lack of spiral artery remodeling described in these studies 
have long been associated with preeclampsia in humans [22].  
 In summary, our studies reveal a critical function for a fetal-derived trophoblast 
factor, AM, in the maternal adaptation to pregnancy. The increased clinical usage of MR-
proADM plasma levels as a biomarker for a variety of cardiovascular conditions underscores 
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the importance of exploring AM as a biomarker for preeclampsia [2]. Finally, since the CLR 
receptor is already being exploited as a pharmacological target for the treatment of migraine 
[23,24], it is conceivable that direct targeting of the CLR-AM axis may hold tremendous 
clinical benefit for the improvement of pregnancy outcomes. 
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FIGURES 
 
  
 
Figure 2-1. Genetic over-expression of fetal Adm facilitates spiral artery remodeling and 
drives uNK recruitment to the decidua 
A. Adm
hi/hi
 placentas have appropriate spiral artery remodeling and are indistinguishable from 
their wildtype littermates. B,C. DBA staining reveals that Adm
hi/hi
 placentas have a 
statistically significant 30% increase in numbers of uNK cells in the decidua compared to 
Adm
+/+  
 littermate placentas. Data are expressed as mean +/- s.e.m. 
 
  
A. 
B. C. 
38 
 
 
 
 
 
 
Figure 2-2. AM dosage alters the cytokine and chemokine milieu of the placenta 
Using a mouse Chemokines and Receptors array platform, the expression of 85 chemokines, 
cytokines, and related proteins was evaluated in placental RNA extracts from Adm
-/-
, Adm
hi/hi
 
and their respective wildtype littermates. Adm
hi/hi
 placentas showed significant elevations in 
numerous cytokines and chemokines that were concomitantly down-regulated in placentas 
from Adm
-/-
 mice, including Ccl 7, Ccl 17, Cxcl10, Xcl1, and TNF. 
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Figure 2-3. Model of fetal-derived AM action at the maternal-fetal interface 
AM and its G protein-coupled receptor, CLR, are highly expressed in parietal trophoblast 
cells at the maternal-fetal interface at midgestation. The genetic dosage of fetal AM is 
directly proportional to the content of maternal uNK cells and their secreted chemokines, 
cytokines, and MMPs within the placenta. As a consequence, AM expression in fetal 
trophoblast cells is necessary for appropriate branching of the fetal vasculature and 
remodeling of maternal spiral arteries. Overexpression of AM within the fetal compartment 
is sufficient to promote uNK recruitment and activation in the decidua, a process that likely 
contributes to AM-induced activation of MMP9 and maternal spiral artery remodeling. 
  
Trophoblast 
Cell 
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Chapter 3: Adrenomedullin Signaling Pathway Polymorphisms and Adverse Pregnancy 
Outcomes
5
 
 
Overview 
Objective: Reduced maternal plasma levels of the peptide vasodilator adrenomedullin 
have been associated with adverse pregnancy outcomes. We measured the extent to which 
genetic polymorphisms in the adrenomedullin signaling pathway are associated with birth 
weight, glycemic regulation, and preeclampsia risk. 
Study Design: We genotyped 1353 women in the Pregnancy, Infection, and Nutrition 
Postpartum Study for 37 ancestry-informative markers and for single-nucleotide 
polymorphisms (SNPs) in adrenomedullin (ADM), complement factor H variant (CFH), and 
calcitonin receptor-like receptor (CALCRL). We used linear and logistic regression to model 
the association between genotype and birth weight, glucose loading test (GLT) results, 
preeclampsia, and gestational diabetes (GDM). All models were adjusted for pregravid BMI, 
maternal age, and probability of Yoruban ancestry. P values of <0.05 were considered 
statistically significant. 
Results: Among Caucasian women, ADM rs57153895, a proxy for rs11042725, was 
associated with reduced birth weight z-score. Among African-American women, ADM 
rs57153895 was associated with increased birth weight z-score. Two CALCRL variants were 
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associated with GDM risk. CFH rs1061170 was associated with higher GLT results and 
increased preeclampsia risk. 
Conclusion: Consistent with studies of plasma adrenomedullin and adverse 
pregnancy outcomes, we found associations between variants in the adrenomedullin 
signaling pathway and birth weight, glycemic regulation, and preeclampsia. 
 
Introduction 
 Adrenomedullin (ADM - human gene, Adm - mouse gene, AM - peptide), a peptide 
hormone vasodilator, plays critical roles in female reproductive biology. Evidence from a 
wide range of in vitro experiments, rat and mouse models, as well as human studies strongly 
supports the fact that AM is essential in the establishment and maintenance of a healthy 
pregnancy [1]. Throughout the course of a normal human pregnancy, AM in the maternal 
plasma increases, peaking at levels three- to five-fold higher than in the nonpregnant state [2-
7] by the third trimester. Precise regulation of maternal AM levels may be necessary in 
healthy pregnancies, as complications including gestational diabetes [8], preeclampsia [7,9-
13], and preterm labor [14,15] have all been associated with perturbations in AM protein 
levels. 
AM mediates its effects via several signaling components, including its receptor, 
calcitonin receptor-like receptor (CALCRL – human gene, CLR - protein), and complement 
factor H (CFH), a protein that binds directly to AM and enhances its activity [16]. Several 
single-nucleotide polymorphisms (SNPs) in ADM, CALCRL, and CFH have been associated 
with health complications including dysglycemia [17] (ADM rs11042725), gestational 
hypertension [13] and decreased urinary sodium excretion [18] (ADM rs3814700), glaucoma 
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[19] (CALCRL rs1157699, rs6759535, and rs840617), essential hypertension in women [20] 
(CALCRL rs696574), reduced birth weight [21] (CALCRL rs698576), age-related macular 
degeneration [22] (CFH rs1061170), and susceptibility to meningococcal disease [23] (CFH 
rs1065489). However, despite what is known about the important role of AM in 
reproduction, very few of these studies have addressed the association of genetic 
polymorphisms in ADM and its signaling partners with adverse pregnancy outcomes. 
Therefore, we sought to measure the extent to which SNPs in ADM, CALCRL, and CFH are 
associated with birth weight, glycemic regulation in pregnancy, and preeclampsia risk in a 
secondary analysis of a prospective cohort study among Caucasian and African-American 
women in central North Carolina. 
 
Materials and Methods 
The Pregnancy, Infection, and Nutrition (PIN) Cohort study comprises three 
prospective cohorts of more than 5000 women enrolled in early to mid-pregnancy. The 
study’s primary goal was to identify risk factors for preterm birth in a prospective fashion. 
Participants enrolled in PIN1 and PIN2 were 24-29 weeks gestation at study entry, and were 
recruited from University of North Carolina Resident and Private Physician Obstetrics Clinic 
and the Wake County Department of Human Services and Wake Area Health Education 
Center prenatal care clinics from August 1995 through June 2000. Subjects enrolled in PIN3 
were less than 20 weeks gestation at study entry and were recruited from the prenatal clinics 
at UNC hospitals from January 2001 to June 2005. The Institutional Review Board of the 
University of North Carolina at Chapel Hill approved the study. Women who consented for 
genetic studies and had extracted DNA available were eligible for inclusion in this analysis. 
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Maternal consent and DNA extracted from peripheral blood was available for 1480 
pregnancies. We allowed for only one pregnancy during the study period. If data were 
available for multiple pregnancies (N=20), we included the pregnancy with the most 
complete SNP data (n = 1460). We further excluded participants with discordant self-
reported race and ancestry estimates calculated from genotyped ancestry informative markers 
(n=5) or failed genotyping in >20% of the ancestry markers (N=64), leaving 1391 eligible 
participants. Finally, we excluded women who were missing data on pre-gravid BMI (n=38), 
leaving 1354 women available for analysis, of whom 940 were non-Hispanic Caucasian and 
413 were non-Hispanic African-American. 
 
Determination of pre-gravid BMI  
Pre-gravid BMI was calculated based on self-reported pre-gravid weight and height at 
the first prenatal visit. Self-reported pre-gravid weights were examined for biological 
plausibility and imputed if deemed appropriate (<5% of weights were imputed) according to 
a previously-described algorithm [24].
 
This imputed weight was calculated using the 
measured weight at the first prenatal visit (if taken prior to 15 weeks) minus the 
recommended amount of weight to be gained in the first and second trimesters as defined by 
the Institute of Medicine [25]. 
 
Study covariates 
The PIN datasets include information from telephone interviews, self-administered 
questionnaires, medical chart abstraction, and biological specimen collection. Information on 
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race/ethnicity (non-Hispanic Caucasian, non-Hispanic African-American, and other) and 
maternal age was self-reported by the mother.  
 
Outcome assessment 
Birth weight z-score was determined using reference populations for sex and self-
reported race [26]. Glucose homeostasis was evaluated using glucose loading test (GLT) 
screening results, which study participants underwent as part of routine clinical care at 24-29 
weeks gestation. Trained abstractors ascertained gestational diabetes through prospective 
review of prenatal records. Participants with GLT values ≥140 mg/dL at UNC sites or ≥130 
mg/dL at Wake County sites underwent a diagnostic 100g oral glucose tolerance test 
(OGTT). Individuals with 2 or more values above established cut points (fasting >95 mg/dL, 
1 hour >180mg/dL, 2 hour > 155 mg/dL, 3 hour >140mg/dL ) were diagnosed with 
gestational diabetes [27].  
To ascertain preeclampsia and gestational hypertension, trained abstractors reviewed 
prenatal and intrapartum records. Prenatal records were abstracted according to the following 
criteria. For PIN 1 and 2 (enrolled 1995-2000), gestational hypertension was defined by 
contemporary American College of Obstetricians and Gynecologists (ACOG) criteria as 
either SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or SBP increase ≥ 30 mmHg or DPB increase 
≥15 mmHg over baseline measured at < 20 weeks’ gestation. For PIN 3 (enrolled 2001-
2005), gestational hypertension was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg with 
previously normal blood pressure. Preeclampsia was defined as gestational hypertension with 
a urine dipstick ≥ 1+ or ≥ 300 mg of protein in a 24-hour urine. Intrapartum records were 
reviewed for physician-recorded diagnosis of either isolated gestational hypertension or 
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preeclampsia. In some cases, prenatal records and clinical intrapartum diagnoses were 
discordant. Among participants with discordant results for prenatal record and intrapartum 
physician diagnosis of preeclampsia or gestational hypertension (N = 125), we further 
reviewed the full intrapartum record. Gestational hypertension was defined as SBP ≥ 140 
mmHg or DBP ≥ 90 mmHg, and preeclampsia was defined as gestational hypertension with 
concurrent proteinuria (≥ 300 mg protein in a 24 hour urine, dipstick ≥ 1+, or urine protein to 
creatinine ratio ≥ 0.14). Isolated gestational hypertension was defined as gestational 
hypertension in the absence of proteinuria. 
 
Genotyping 
Genotyping for 8 SNPs was performed at the Children’s Hospital of Boston using the 
Sequenom iPLEX platform [28]. We genotyped SNPs in ADM, CALCRL, and CFH 
previously reported to be associated with adverse health outcomes [13,17-23]. All SNPs were 
tested for Hardy-Weinberg equilibrium among self-identified Caucasian participants using a 
threshold of p < 0.001. 
 
Population stratification 
In genetic association studies, differences in allele frequency among ethnic groups 
can confound relationships between genotype and disease outcome. To address population 
stratification in this cohort, genotyping was performed for 37 ancestry-informative markers 
that have been used successfully in other genetic association studies [29]. STRUCTURE was 
used to infer population substructure and assign individuals to populations using probabilistic 
clustering methods [30]. We analyzed self-identified Caucasian and African-American 
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participants separately, and we included probability of Yoruban ancestry as a covariate 
among self-identified African-American women. 
 
Statistical analysis 
We used linear regression to model associations between maternal genotype and birth 
weight z-score and glucose loading test (GLT) results, adjusting for maternal age, pregravid 
BMI, and pregravid BMI squared. We included a quadratic term to allow for non-linear 
associations between pregravid BMI and outcomes of interest. We used maximum likelihood 
logistic regression to model associations between maternal genotype and diagnosis of 
gestational diabetes or preeclampsia, adjusting for maternal pregravid BMI and age. In both 
models, we considered the association of the risk allele to be additive. 
We excluded from logistic regression analysis SNPs for which there were fewer than 
5 cases among minor allele carriers. Because the purpose of our study was exploratory rather 
than confirmatory, adjustment for multiple comparisons was not performed. Thus in this pilot 
study, p values of <.05 were considered statistically significant. 
 
Results 
A total of 940 Caucasian and 413 African-American women were included in our 
analysis. African-American participants were younger, had a slightly higher pregravid BMI, 
and delivered earlier than Caucasian participants (Table 3-1). Infants born to African-
American mothers had lower birth weights and mean birth weight z-scores than infants born 
to Caucasian mothers (t-test p < .01). GLT results, GDM, and preeclampsia rates were 
similar in the two groups (Table 3-2).  
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Table 3-3 shows the associations between the ADM signaling pathway genetic 
variants of interest and pregnancy outcomes. Significant (p<0.05) associations are 
highlighted in bold in the table. Among Caucasian women, ADM rs57153895, a proxy for 
rs11042725, was associated with reduced birth weight z-score (-0.10 per G allele, 95% CI -
0.19 to -0.01). Among African-American women, ADM rs57153895 was associated with 
increased birth weight z-score (0.18 per G allele, 95% CI 0.03 to 0.34). Two variants in 
CALCRL, rs69696574 and rs840617, were associated with increased GDM risk (rs69696574: 
OR 2.35 per C allele, 95% CI 1.04-5.27 and rs840617: OR per T allele, 2.66, 95% CI 1.13-
6.25). CFH rs1061170 was associated with higher GLT results (4.39 mg/dL per T allele, 95% 
CI 0.22 to 8.57) and with increased preeclampsia risk (OR 2.02 per T allele, 95% CI 1.11-
3.68). Table 3-4 summarizes these SNPs, the human diseases they have been previously 
associated with, and their significant associations with pregnancy outcomes in the current 
study. 
 
Comment 
Consistent with studies of plasma AM and pregnancy complications, we found 
associations between variants in AM signaling pathway components and birth weight, 
glycemic regulation, gestational diabetes, and preeclampsia. These findings support our 
hypothesis that genetic variants in ADM, its receptor, CALCRL, and its binding protein CFH, 
that have previously been shown to be associated with disease conditions are also associated 
with adverse pregnancy outcomes. 
We found that an ADM variant previously associated with dysglycemia [17] in non-
pregnant populations, rs57153895 (a proxy for rs11042725), was associated with birth 
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weight. This variant had opposing effects depending on race, as it was associated with lower 
birth weight in Caucasian women but higher birth weight among African-American women, 
which may reflect differences in linkage disequilibrium patterns in Caucasian versus African-
American women. The association between AM and birth weight described here is consistent 
with previous studies that have shown a relationship between AM and fetal growth. 
Antagonism of AM has been shown to cause intrauterine growth restriction in the rat, [31,32] 
and female mice that are haploinsufficient for Adm have pregnancies with increased rates of 
fetal growth restriction [33]. Most recently, using Adm knockout mice, we have shown that 
fetal-derived AM is required for the maternal vascular adaptation to pregnancy [34]. 
Alterations in AM levels have also been associated with fetal growth in studies in human 
populations [35-38]. Our finding of a genetic variant in ADM associated with birth weight 
provides further evidence for the importance of maternal AM in fetal growth. 
Complement factor H, another important component of the AM signaling paradigm, 
binds to AM and enhances its activity [16]. Here, we found that the CFH variant rs1061170, 
previously associated with age-related macular degeneration [22], was associated with higher 
GLT results and increased preeclampsia risk among African-American women. Circulating 
levels of CFH have been shown to negatively correlate with insulin sensitivity in human 
subjects [39]. Consistent with this previous finding, our results suggest a role for CFH in 
glucose tolerance, which may be especially important during pregnancy. Furthermore, this 
CFH variant was also associated with increase preeclampsia risk, which is of particular 
interest given that dysregulated activation of complement is known to play a role in the 
pathogenesis of preeclampsia [40]. 
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CLR, as the G protein-coupled receptor for AM, is an essential mediator of AM’s 
effects, and one study, which showed an association between a CALCRL SNP and reduced 
birth weight in an African-American population [21], has pointed to the importance of 
CALCRL variants in human pregnancy. Two of the CALCRL variants tested here, rs696574 
and rs840617, were previously shown to be associated with essential hypertension in women 
[20] and with glaucoma [19], respectively. Though we did not find an association with 
hypertension in this pregnant population, in the present study we found evidence that CLR 
does play a role in glycemic regulation during pregnancy, as both of CALCRL variant 
rs696574 and rs840617 were associated with increased gestational diabetes risk in African-
American women. 
Our study has several strengths, including our use of ancestry informative markers to 
control for population stratification and prospective ascertainment of outcomes within a 
pregnancy cohort. However, our results must be interpreted in the context of the study 
design. The small number of cases of GDM and preeclampsia led to large confidence 
intervals around estimates of association. In addition, pre-pregnancy weight was self-
reported. Furthermore, multiple testing is a concern. We limited our analysis to variants 
known to be associated with disease outcomes in other studies, but it is possible that our 
findings are due to chance, and further studies will be needed to validate observed 
associations. Furthermore, future studies should be directed at determining the mechanisms 
by which these ADM, CALCRL, and CFH polymorphisms may alter ADM activity. An ADM  
SNP that was not part of our analysis has been shown to associate with lower plasma ADM 
levels [41]. Thus, it is biologically plausible that the SNPs included in our study may 
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similarly affect ADM levels or alternatively, ADM activity through its signaling partners, 
CALCRL and CFH. 
Taken together, these results support the central role for the AM signaling pathway in 
human pregnancy and pregnancy complications. Future studies are needed to determine 
whether screening for maternal genotype of these SNPs could be used to identify women at 
risk for adverse pregnancy outcomes. 
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TABLES 
 
Table 3-1: Study population 
 Caucasian Non-Hispanic African-
American 
N 940 413 
Maternal age (mean (SD)) 28.3 (6.1) 24.0 (5.4) 
Pregravid BMI (mean (SD)) 25.1 (6.5) 27.8 (8.3) 
Gestational age at birth, 
median (IQR) 
39.3 (37.7, 40.3) 38.9 (36.7,40.1) 
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Table 3-2: Outcomes of interest 
 N* Non-Hispanic 
Caucasian 
N* Non-Hispanic 
African-American 
  Mean (SD)  Mean (SD) 
Birth weight, g 933 3275 (651) 402 2953 (733) 
Birth weight z 
score 
933 0.002 (1.00) 398 -0.460 (1.04) 
GLT, mg/dL 842 108.5 (26.3) 366 105.9 (31.7) 
  N (%)  N (%) 
GDM 899 56 (6.2) 386 24 (6.2) 
Preeclampsia 940 47 (5.0) 413 30 (7.3) 
 
* Number of participants with outcome data available 
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Table 3-3: Associations between genetic variants in the adrenomedullin pathway and 
pregnancy outcomes 
Gene SNP_ID Re
f 
Other Other 
allele 
fraction 
Birth weight 
z-score
1
 
GLT 
(mg/dL)
1
 
GDM OR
2
 Preeclampsia 
OR
2
 
Caucasian         
ADM 
4
 rs57153895 A G 
0.48 
-0.10 
(-0.19, -0.01) 
-0.64 
(-3.10, 1.81) 
1.05 
(0.72-1.54) 
1.5 
(0.69-2.59) 
ADM
 4
 rs7935242 T C 
0.52 
0.08 
(-0.01, 0.17) 
0.81 
(-1.68, 3.30) 
0.98 
(0.67-1.45) 
0.95 
(0.62-1.44) 
CALCRL rs1157699 C T 
0.32 
-0.03 
(-0.12, 0.07) 
-1.95 
(-4.54, 0.64) 
0.79 
(0.51-1.22) 
1.39 
(0.91-2.13) 
CALCRL rs6759535 T C 
0.54 
-0.07 
(-0.16, 0.02) 
-0.50 
(-2.97, 1.97) 
0.80 
(0.54-1.17) 
1.09 
(0.72-1.67) 
CALCRL rs696574 T C 
0.85 
0.04 
(-0.08, 0.17) 
1.38 
(-2.11, 4.87) 
1.45 
(0.79-2.66) 
0.78 
(0.46-1.35) 
CALCRL rs840617 A T 
0.85 
0.04 
(-0.09, 0.16) 
1.49 
(-1.98, 4.95) 
1.42 
(0.78-2.61) 
0.89 
(0.50-1.57) 
CFH rs1061170 C T 
0.59 
-0.02 
(-0.11, 0.08) 
0.37 
(-2.17, 2.90) 
1.14 
(0.77-1.71) 
1.29 
(0.83-2.00) 
CFH rs1065489 G T 
0.17 
-0.06 
(-0.18, 0.06) 
-0.19 
(-3.47, 3.09) 
1.37 
(0.85-2.21) 
1.30 
(0.77-2.20) 
African-
American
3
 
        
ADM  rs57153895 A G 0.29 
0.18 
(0.03, 0.34) 
3.83 
(-0.9, 8.57) 
1.42 
(0.78-2.59) 
0.70 
(0.38-1.32) 
ADM  rs7935242 T C 0.77 
-0.16 
(-0.33, 0) 
-4.18 
(-9.2, 0.84) 
0.77 
(0.40-1.50) 
1.11 
(0.58-2.10) 
CALCRL rs1157699 C T 0.16 
0.03 
(-0.15, 0.22) 
-3.53 
(-8.96, 1.89) 
1.26 
(0.65-2.44) 
0.42 
(0.16-1.11) 
CALCRL rs6759535 T C 0.42 
-0.06 
(-0.2, 0.09) 
-3.96 
(-8.27, 0.35) 
0.70 
(0.38-1.27) 
0.68 
(0.39-1.18) 
CALCRL rs696574 T C 0.71 
0.00 
(-0.16, 0.16) 
0.16 
(-4.87, 5.19) 
2.35 
(1.04-5.27) 
0.66 
(0.38-1.17) 
CALCRL rs840617 A T 0.71 
-0.01 
(-0.17, 0.15) 
0.41 
(-4.52, 5.34) 
2.66 
(1.13-6.25) 
0.68 
(0.39-1.21) 
CFH rs1061170 C T 0.61 
-0.08 
(-0.22, 0.06) 
4.39 
(0.22, 8.57) 
1.80 
(0.95-3.42) 
2.02 
(1.11-3.68) 
CFH rs1065489 G T 0.05 
-0.03 
(-0.34, 0.28) 
6.17 
(-3.43, 
15.77) -- 
5
 --- 
5
 
Bold indicates p < 0.05 
1 
Linear regression model, effect estimate (95% CI) per other allele, adjusting for pregravid BMI, 
BMI squared, and maternal age 
2
 Logistic regression model, OR (95% CI) per other allele, adjusting for pregravid BMI and maternal 
age 
3 
Adjusted for probability of Yoruban ancestry 
4
 Proxies for ADM rs11042725  
5
 Excluded from logistic regression due to < 5 cases among women carrying one or two copies of the 
minor allele 
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Table 3-4: Summary of ADM, CALCRL, and CFH SNPs, their previously reported 
disease associations, and significantly associated pregnancy complications in the 
current study 
 
 
SNP 
Previously Reported 
Disease Association 
Association with 
Pregnancy Outcomes 
ADM rs57153895 Dysglycemia [17] 
Decreased birth weight (Caucasian) 
Increased birth weight (African-American) 
CLR rs696574 
Essential hypertension 
in women [20] 
Increased gestational diabetes mellitus risk 
(African-American) 
CLR rs840617 Glaucoma
 
[19] 
Increased gestational diabetes mellitus risk 
(African-American) 
CFH rs1061170 
Age-related 
macular degeneration 
[22] 
Higher glucose loading test result 
(African-American)  
Increased preeclampsia risk 
(African-American) 
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Chapter 4: Conclusions and Future Directions 
 
Summary of Results 
These studies have uncovered several novel aspects of the role of AM and its 
signaling partners in pregnancy and pregnancy complications. In the work presented in 
Chapter 2, mouse models revealed that placentas of Adm
hi/hi
 pups have appropriately 
remodeled spiral arteries and a significant increase in uNK cell numbers. Thus, fetal 
overexpression of Adm reverses the preeclampsia-like placental phenotype observed in the 
placentas of Adm
-/-
 pups, and increases recruitment of maternal uNK cells to the decidua. 
Furthermore, the expression of numerous cytokines and chemokines are oppositely regulated 
in the placentas of Adm
hi/hi 
pups compared to Adm
-/-
 placentas, indicating that fetal dosage of 
AM alters the innate immune milieu of the placenta via its effects on uNK cells. These 
results are part of a larger study revealing that fetal AM is an essential factor in fetal-
maternal communication required for the maternal vascular adaptation to pregnancy. 
 The human genetics study undertaken in Chapter 3 revealed that ADM genotype is 
also an important factor in human pregnancy. SNPs in ADM, its receptor, CALCRL, and its 
binding partner, CFH, are significantly associated with birth weight, glycemic regulation in 
pregnancy, gestational diabetes, and preeclampsia. SNPs in ADM and its signaling partners 
are associated with adverse pregnancy outcomes, and this study supports the central role for 
the AM signaling pathway in human pregnancy and pregnancy complications. 
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Current State of the Field - Adrenomedullin, Pregnancy, and Pregnancy Complications 
 The studies presented here contribute to our understanding of adrenomedullin 
signaling in female reproduction. However, there is still much to learn. There are numerous 
areas of active, ongoing research in this field, a few of which are highlighted here. 
 
Immune cells, adrenomedullin, and the placenta 
 AM has long been known to have effects on the immune system, and our results 
presented in Chapter 2 begin to address how these effects may be relevant in pregnancy and 
pregnancy complications. The roles of various immune cells in the placenta are an important 
focus area of established and emerging research in the pregnancy field.  
 Uterine NK cells are the most abundant leukocyte population in the placenta. Unlike 
peripheral NK cells, uNK cells have low cytotoxicity [1], indicating that this cell population 
has functions unique to the placental bed. As noted in Chapter 2, uNK cells are known to 
produce a wide variety of cytokines, and one role of these cytokines is the regulation of 
trophoblast invasion [2,3]. Our study also complements an existing body of knowledge 
indicating that uNK cells are required for spiral artery remodeling [4,5]. In addition to 
cytokines, the angiogenic factors Ang-2 and VEGF-C are also likely involved in mediating 
this effect [6,7]. Very recently, a few studies have suggested that uNK cells may also have 
another role during pregnancy – controlling placental infections, such as Toxoplasma gondii 
and human cytomegalovirus [8,9]. Aside from our study of uNK cells in Adm
+/-
 and Adm
hi/hi
 
mouse placentas, the role of AM in modulating the various effects of uNK cells remains 
largely unknown. Numerous studies have also attempted to translate these findings to human 
pregnancy by determining whether uNK cell numbers are altered in pregnancy 
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complications, with conflicting results. Different reports have shown increased or no change 
in uNK cell numbers in cases of recurrent or sporadic miscarriage, and studies have shown 
both increased and decreased uNK cell numbers in placentas of patients with preeclampsia or 
fetal growth restriction (reviewed by Lash et. al., [10]). Thus, it is not yet clear how uNK cell 
numbers are altered in pregnancy complications; additional research is needed to help to 
clarify the importance of uNK cells in human pregnancy and mechanistically study what role 
AM plays in their regulation. 
 Current research also points to important roles for several other immune cell 
populations in pregnancy. Macrophages are the second largest population of leukocytes in 
the placenta after uNK cells. They are thought to play roles in phagocytosis of cell debris, 
maternal immunosuppression, and trophoblast invasion, and macrophage populations may be 
altered in pregnancy complications such as preeclampsia and miscarriage [11]. AM is known 
to induce cytokine production in peripheral-type macrophages [12], so it is possible that AM 
also regulates placental macrophages, but this has not yet been studied. Dendritic cells are 
another immune cell type found at the fetal-maternal interface. Like macrophages, dendritic 
cells are important in immune regulation of maternal tolerance during pregnancy. More 
recently, dendritic cells have also been found to have angiogenic effects in a variety of 
settings, and may similarly stimulate angiogenesis during implantation and placentation [13]. 
Further complicating the picture of immunology at the fetal-maternal interface, crosstalk 
between trophoblast cells and different immune cell populations is also likely to be important 
– for example, uNK and dendritic cell interactions are modulated by trophoblast cells in vitro 
[14], and uNK cells have recently been shown to regulate dendritic cell function during 
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murine pregnancy [15]. Future studies in this field may help tease out the relative roles of the 
different immune cells within the placenta and the effects AM may have in this context. 
 
Adrenomedullin, cigarette smoke, and preeclampsia risk 
 Our data clearly demonstrate that the fetal levels and genotype of Adm are the critical 
determinants of its function at the maternal-fetal interface. Therefore, to further the field it is 
important to identify genetic, physiological, and environmental factors that regulate the 
expression Adm within the fetal trophoblast cell. In this regard, it has long been appreciated 
that estrogen and hypoxia can potently upregulate Adm gene expression in a variety of cell 
types, including those of reproductive relevance [16,17]. 
Most interestingly, it has recently become clear that cigarette smoke, likely acting 
through two functional aryl-hydrocarbon response elements proximal to the Adm start codon 
[18], can also potently induce Adm expression in trophoblast cells [19]. Trophoblast cells 
exposed to cigarette smoke extract (CSE) have increased cell viability and increased cell 
migration, and these effects are ablated by co-treatment with an AM inhibitor [19]. 
Moreover, the exposure of humans and mice to cigarette smoke during pregnancy has 
recently been linked to a statistically significant increase in uNK cells [20]. Thus, although 
cigarette smoking during pregnancy has a wide range of deleterious effects, the cigarette 
smoke-induced upregulation of Adm gene expression in fetal trophoblast cells, and the 
potentially subsequent increase in uNK cells, may provide the mechanistic link for 
explaining the decades-old clinical observation that moderate smoking during pregnancy is 
actually protective against preeclampsia [21,22]. The link between AM, smoking, and 
preeclampsia is an emerging area of interest in the field and is one that has great potential to 
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further our understanding of the mechanism behind AM- and cigarette smoke-induced 
preeclampsia prevention. 
 
Adrenomedullin and screening approaches for pregnancy complications 
 In vitro studies and mouse models have added much to our understanding of how AM 
functions during pregnancy. Attempting to translate this knowledge for the development of 
useful clinical tools is a major area of focus in the field. As discussed in Chapter 1, numerous 
studies have shown that AM levels are altered in a variety of pregnancy complications, 
including gestational diabetes, fetal growth restriction, preterm birth, and preeclampsia [23]. 
However, studies of AM levels in pregnancy have historically been variable due to the 
relative instability of the peptide and a lack of consistency in the assays that are used to 
measure it. However, the measurement of the highly stable peptide hormone precursor of 
AM, midregional pro-adrenomedullin (MR-proADM), can now be performed with such a 
high level of accuracy that it is showing great clinical value in the context of predicting poor 
outcomes following myocardial infarction, sepsis, and community acquired pneumonia [24]. 
The latest studies have found that MR-proADM levels are associated with cardiovascular risk 
factors [25] and correlate with renal function [26]. 
Of particular relevance to the field of reproductive research, recent studies have also 
found connections between MR-proADM and adverse events in the perinatal period. Smith 
et. al. showed that MR-proADM levels in neonates are affected by delivery-related fetal 
stress and fetal acid-base balance [27], and Admaty et. al found that MR-proADM levels in 
newborns correlate with prematurity and the incidence of perinatal infections [28]. With 
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additional research, AM has great potential to be developed as a biomarker or perhaps even 
therapeutic target in pregnancy and related complications. 
 
Future Directions 
 The studies presented here contribute to our understanding of the role of AM in 
modulating the immune milieu of the placenta, and we have also found associations between 
AM signaling system SNPs and various adverse pregnancy outcomes. These exciting data 
can be built upon in future studies to gain greater mechanistic insight into these phenomena. 
 
Future studies pertaining to AM and uterine NK cells 
 The data presented in Chapter 2, along with other data from the Caron Laboratory, 
show that fetal-derived AM is required for the appropriate remodeling of maternal spiral 
arteries—a novel demonstration of the importance of fetal-to-maternal communication 
during pregnancy. Moreover, we show that the dosage of fetal-derived AM directly 
influences the content and function of maternal uNK cells in the placenta. Future studies 
should be directed toward further elucidating the distinct cellular process and molecular 
mechanisms that govern the effects of AM on spiral artery remodeling and distinguishing the 
cell types responsible for mediating these effects.  
A major aspect of spiral artery remodeling is the degradation of the surrounding 
extracellular matrix by proteases and peptidases. Numerous studies have identified critical 
roles for the matrix metalloproteinase 9 (MMP9) and placental-specific cathepsins in this 
process. Preliminary data generated by a previous postdoctoral researcher in the Caron 
Laboratory made use of our uNK cell conditioned media protocol (described in [29]) coupled 
Figure 10 
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with qRT-PCR and zymography gelatin gel quantification. This data shows that AM-
conditioned media obtained from uNK cells results in significantly higher MMP-9 activity 
levels (Figure 4-1A,B). Cathepsin S, which normally appears as a prominent band tightly 
surrounding appropriately remodeled wildtype spiral arteries, was found to be less evident 
and diffusely spread around spiral arteries of Adm
-/-
 placentas (Figure 4-1C). However, 
because MMP9 and cathepsins are expressed and secreted by both trophoblast cells and 
decidual cells (including uNK cells), we cannot currently ascribe the in vivo phenotypes to 
either or both cell types. To address this question, future studies could make use of both 
primary isolated uNK cells and trophoblast cells (HTR8-SvNeo cells) in order to evaluate the 
effects of AM treatment on MMP9 and cathepsin activities. uNK or trophoblast cells could 
be treated with increasing doses of AM and an inhibitor of AM, AM22-52. The effects of 
AM treatment on MMP and cathepsin activity can then be evaluated in the presence and 
absence of commercially available, specific MMP inhibitors and cathepsin inhibitors. In 
combination with the preliminary data already generated, these studies will elucidate whether 
uNK cells, trophoblast cells, or both, are important contributors to the MMP9 and cathepsin 
activity required for spiral artery remodeling. 
We have shown that loss of fetal AM results in significantly reduced uNK cells at the 
maternal-fetal interface. In contrast, overexpression of AM in Adm
hi/hi 
placentas has the 
opposite effect, resulting in more uNK cells. This raises the question of whether AM itself, in 
the absence of uNK cells, can directly contribute to spiral artery remodeling through its 
actions on other cell types. Many studies in the literature describe potent functions of AM on 
the vasculature and other immune cells, including endothelial cells [30,31], vascular smooth 
muscle cells [30], and macrophages [12]. To determine whether uNK cells are required to 
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mediate the effects of AM on spiral artery remodeling, we could cross Adm
hi/hi  
 mice onto the 
NK cell-deficient mouse line, Tg26, available from Jackson Laboratory. This mouse line is 
homozygous for the (CD3E)26Cpt transgene and lacks NK cells and mature T lymphocytes. 
Multiple studies have confirmed that placentas of Tg26 mice fail to remodel spiral arteries 
[32]. Using this model, future studies could compare the effects of high endogenous fetal AM 
on spiral artery remodeling, in the presence or absence of uNK cells. For the phenotypic 
evaluation, we could perform experiments similar to those used to characterize the placentas 
of our Adm
-/-
 and Adm
hi/hi 
mice, including -smooth muscle actin staining, 
proliferation/apoptosis assays, cytokine profiling, and MMP or cathepsin activity assays. If 
AM can ameliorate or rescue the defective spiral artery remodeling of Tg26 mice, without 
uNK cells, then this would suggest that AM peptide can directly act as a modulator of 
vascular remodeling through other mechanisms. On the other hand, if increased AM levels 
are unable to ameliorate the defective spiral arteries, then this will re-emphasize the 
requirement of direct communication between trophoblast-derived AM and uNK cells. 
Results from these future studies would be essential in piecing together the mechanism by 
which AM is involved in spiral artery remodeling and its potential role in preventing the 
pathological features of preeclampsia. 
 
Future studies pertaining to AM, cigarette smoke, and preeclampsia 
 As discussed in the previous section, cigarette smoke extract (CSE) induces AM 
expression in trophoblast cells [19], and smoking during pregnancy has been linked to 
reduced preeclampsia risk [21,22]. We have hypothesized that the upregulation of AM may 
in fact be the mechanism underlying the protective effects of cigarette smoking. To pursue 
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this hypothesis, the Caron Laboratory has established a collaboration with Dr. Chad Grotegut 
at Duke University, who has studied the effect of CSE on AM expression in trophoblast cells 
in vitro. Future collaborative experiments could first be designed to test the effect of CSE on 
AM in vivo, since this has not yet been studied. Pregnant mice could be exposed to cigarette 
smoke and AM expression in the placenta could be analyzed. Based on the effects of CSE on 
AM in cultured trophoblast cells, the placentas of mice exposed to smoke will likely have 
increased AM expression. We are also interested in determining whether there is a link to 
uNK cells in this phenomenon, so we could use DBA lectin staining to see if uNK cell 
numbers are increased in the placentas of cigarette smoke-exposed mice.  
To further investigate the mechanism of CSE’s effect on AM expression, we could 
generate a construct in which the aryl-hydrocarbon response element in AM’s promoter is 
mutated, rendering it non-responsive to CSE. This mutant construct could be transfected into 
cultured trophoblast cells, and we could then test whether this mutation ablates the increase 
in AM expression normally seen with CSE treatment. After proving this in vitro, we could 
move back in vivo and use gene targeting to generate a mouse model with this same mutation 
in the AM promoter. These mice would also be exposed to smoking, and we would expect 
that placental AM expression and uNK cell numbers would not increase in these mice since 
they cannot respond to cigarette smoke. Future studies could also make use of a preeclampsia 
(PE) mouse model to determine whether cigarette smoke exposure or AM treatment with a 
minipump could reverse the observed pathological features of PE. While Adm
-/-
 placentas do 
develop PE-like features, we would not utilize them for these studies, because a knockout 
animal would be unable to upregulate AM expression. Therefore, for these studies we could 
utilize an established mouse model of preeclampsia, termed the CBA/J x DBA/2 model [33]. 
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We would expect that both AM treatment and CSE may reverse the PE phenotype, and the 
effect of CSE may be AM-mediated. These future studies could be highly informative in 
defining the mechanistic link between cigarette smoking, adrenomedullin, and reduced 
preeclampsia risk. 
 
Future studies pertaining to AM signaling polymorphisms and pregnancy complications 
 The results presented in Chapter 3 have identified SNPs in ADM, CALCRL, and CFH 
that are associated with adverse pregnancy outcomes. This study is the first to correlate 
pregnancy outcomes with SNPs previously associated with other, non-pregnancy related 
disease conditions. However, much remains unknown about the significance of AM signaling 
polymorphisms and pregnancy in human populations. One limitation of our study is that 
there were a relatively small number of gestational diabetes and preeclampsia cases identified 
within our patient cohort. Thus, future studies could utilize a larger study population with a 
greater number of cases for our outcomes of interest, to determine whether the associations 
between the SNPs and pregnancy complications we identified can be further validated. For 
example, a group in the United Kingdom has collected genomic DNA from a cohort of 
almost 14,000 pregnant women [34], so future collaborative efforts could potentially validate 
our findings in this larger population. Genome-wide association studies would be another 
useful approach in theory, but unfortunately, such studies looking at pregnancy 
complications have not yielded definitive results, particularly for preeclampsia [35,36]. 
 If additional cohort studies confirm the association between AM signaling SNPs, 
future studies could also be directed at characterizing the biochemical properties of the 
polymorphic gene product. Mutant ADM, CALCRL, and/or CFH constructs could be cloned 
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that correspond to the SNPs of interest. Established in vitro techniques could then be used to 
determine whether these mutant proteins have altered activity or function. For example, a 
mutation in AM could affect its ability to bind to CLR, or could alter its downstream 
signaling, transcriptional regulation, or the stability of the peptide. 
 Taken together, the results presented here provide additional support for the 
importance of AM in pregnancy, and future studies (in cultured cells, mouse models, and 
human populations) have great potential to further our understanding of the mechanisms by 
which AM functions. 
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FIGURES 
 
 
 
 
 
 
 
Figure 4-1. The effects of AM dosage on placental MMPs and cathepsins 
Preliminary data generated by a previous Caron Lab member showed that A. MMP9 
Expression in isolated uNK cells exhibits a dose-dependent increase with AM treatment. B. 
MMP9 activity is increased in conditioned media from AM-treated uNK cells. C. Spiral 
artery cathepsin S staining is disrupted in Adm
-/-
 placentas compared to wildtype littermates. 
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Chapter 5: The Biochemistry of Receptor Activity Modifying Proteins and their 
Receptor Partners 
 
Introduction 
 In addition to the study of adrenomedullin and pregnancy, the receptor activity 
modifying proteins (RAMPs), components of the AM receptor complex, are a major area of 
research focus in the Caron Laboratory. The RAMPs are a family of single transmembrane 
chaperone proteins that modulate G protein-coupled receptor (GPCR) trafficking, ligand 
binding, and G-protein-coupling efficiency [1,2]. Currently, this family consists of three 
proteins (RAMPs 1-3) sharing a similar molecular mass (160 amino acids) and structure, but 
differing in sequence homology, tissue distribution, and whether they are required for normal 
embryonic development [2-8]. Since their discovery, studies over the last 15 years have 
generated a wealth of knowledge about the RAMP family, though much also remains 
unknown about which GPCRs they interact with and how these proteins function. 
 
The Discovery of the RAMPs 
 The discovery of the RAMPs was reported by McLatchie et. al. in 1998 [2]. The 
RAMPs were first identified in association with the GPCR calcitonin receptor-like receptor 
(CLR), discussed in Part 1 as the receptor for adrenomedullin (AM). Prior to the discovery of 
the RAMPs, there was significant controversy in the field surrounding CLR. Conflicting 
reports existed regarding the subcellular localization of CLR (endoplasmic reticulum or 
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plasma membrane) and there was even disagreement over the true ligand for CLR, as it was 
found by different groups to bind both AM and another peptide, calcitonin gene-related 
peptide, or CGRP [9,10]. The discovery of the RAMPs clarified this controversy by revealing 
that CLR can bind to all three of the RAMPs, which facilitates forward translocation of the 
receptor from the endoplasmic reticulum to the cell surface. Furthermore, when CLR is 
bound to RAMP1, it forms a receptor with a high affinity for CGRP, but when CLR is bound 
to RAMP2 or 3, the complex binds with high affinity to AM [2]. Figure 5-1 models the 
interactions of the RAMP family members with CLR. Thus, it was revealed that RAMPs can 
regulate both GPCR transport and ligand binding specificity. The McLatchie study provided 
a major breakthrough in the study of CLR, and more broadly, introduced a paradigm shift in 
our understanding of GPCR trafficking and function. 
 
Novel Receptor Partners for the RAMP Family 
 The RAMPs were first identified as modulators of CLR trafficking and ligand 
binding. Since that discovery, however, numerous additional roles and receptor partners for 
RAMPs have been uncovered. Calcitonin receptor (CTR), which, like CLR, is a class II 
GPCR and shares over 50% sequence identity with CLR, was identified as another possible 
receptor target for RAMP interaction. The Sexton Laboratory tested this hypothesis, and 
found that while CTR alone binds with highest affinity to calcitonin, co-expression of CTR 
with RAMP1 or RAMP3 formed a receptor that bound with high affinity to another peptide, 
amylin. RAMP2 had no effect on CTR ligand binding [11]. Using tagged constructs, they 
also found that co-expression of CTR and RAMP1 led to translocation of RAMP1 to the cell 
surface. Thus, RAMPs can modulate translocation and ligand binding of both CLR and CTR. 
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Several years later, the Sexton Laboratory published another study, this time 
identifying several additional class II GPCRs that interact with RAMPs [12]. These studies 
utilized confocal microscopy of cells transfected with epitope-tagged versions of the RAMPs, 
expressed with and without the receptors of interest. Similar to their experiments testing 
cellular localization of RAMP1 and CTR described above, receptors that facilitated 
translocation of the RAMPs from the endoplasmic reticulum to the plasma membrane were 
determined to interact with the RAMPs. They found that vasoactive intestinal 
polypeptide/pituitary adenylate cyclase-activated peptide receptor 1 (VPAC1R) interacted 
with all three RAMPs. The glucagon receptor and parathyroid hormone receptor (PTHR) 1 
interacted only with RAMP2, while PTHR2 interacted only with RAMP3. However, no 
differences in ligand binding were observed for VPAC1R with or without the RAMPs. 
Interestingly, the VPAC1R-RAMP2 receptor complex was found to have altered downstream 
signaling compared to VPAC1R expressed alone. However, no functional consequences were 
identified for the interaction of VPAC1R with RAMP1 or RAMP3, nor were functional 
effects found for the interaction of glucagon receptor, PTHR1, or PTHR2 with the RAMPs, 
leaving open the question of what impact RAMP binding has on these receptors.  
Other laboratories interested in GPCR pharmacology also tested novel receptors for 
the ability to interact with RAMPs. Bouschet et. al. showed that calcium sensing receptor 
(CSR), a class III GPCR, depends upon interaction with either RAMP1 or RAMP3 for 
translocation to the plasma membrane. They also showed that RAMP1 and RAMP3 
colocalize and co-immunoprecipitate with CSR, providing further evidence for this 
interaction [13]. Later, Harikumar et. al. showed that the secretin receptor (SecR), a class II 
GPCR, interacts with RAMP3, again via confocal microscopy showing translocation of the 
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RAMP to the cell surface when co-expressed with SecR [14]. This manuscript also made use 
of a new technique, bioluminescence resonance energy transfer (BRET), to show the 
RAMP3-SecR interaction. In BRET studies, first developed for detection of RAMP-GPCR 
interactions by Michel Bouvier’s laboratory [15], cells are co-transfected with a yellow 
fluorescent protein (YFP)-tagged RAMP and a luciferase-tagged receptor of interest. The 
cells are then treated with a luciferase substrate. If the RAMP and receptor are in very close 
proximity to one another, indicating an interaction, resonance energy transfer from the donor 
(luciferase-tagged receptor) to the acceptor (YFP-tagged RAMP) can occur and this specific 
signal is detected (Figure 5-2). Thus, Harikumar et. al. not only showed that SecR interacts 
with RAMP3, but they also were the first group to utilize the Bouvier Laboratory’s BRET 
technique to interrogate a novel RAMP-receptor interaction. 
Most recently, two additional receptor targets for the RAMP family have been 
identified in a collaborative effort between the Poyner Laboratory and the Caron Laboratory. 
This study revealed that VPAC2R, similar to VPAC1R, can facilitate RAMP translocation to 
the cell surface, indicating an interaction [16]. Furthermore, type 1 corticotrophin releasing 
factor receptor (CRF1) interacts with RAMP2, and co-expression of the two enhances 
localization of CRF1 and RAMP2 to the cell surface. The interaction of CRF and RAMP2 
also altered downstream signaling. The RAMP-receptor interactions described here are 
summarized in Table 5-1. 
 
The Pleiotropic Effects of RAMPs on GPCRs 
The initial studies identifying and characterizing the RAMPs, described above, also 
ascertained many of the effects RAMPs can have on their GPCR partners. The ability of 
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RAMPs to alter receptor ligand binding specificity and to facilitate forward translation of 
receptors to the cell surface are two of these effects. However, additional research has 
revealed that these are not the only ways in which RAMP interactions can influence GPCRs. 
Figure 5-3 models the variety of effects RAMPs have on GPCR function. 
  
RAMPs and downstream signaling 
The first evidence of the additional ways in which RAMPs can modulate GPCR 
activity came from the studies describing the interaction of RAMP2 with VPAC1R, already 
briefly described. In addition to showing that VPAC1R and RAMP2 co-expression causes 
translocation of RAMP2 to the cell surface, the VPAC1R-RAMP2 receptor complex was 
shown to have enhanced agonist-mediated phosphoinositide hydrolysis without a change in 
cAMP stimulation, in comparison to VPAC1R expressed alone [12]. Thus, a new role for the 
RAMP family was discovered – the ability to alter receptor downstream signaling. Morfis et. 
al. also found differences in downstream signaling with RAMPs. In this study, the authors 
showed that expression of CTR with RAMP1 or RAMP3 leads to a 20- to 30-fold increase in 
the potency of cAMP induction with amylin binding, but only a 2- to 5-fold increase in 
potency for calcium signaling or ERK1/2 activation, which are other signaling pathways 
downstream of CTR [17]. Furthermore, the CTR/RAMP3 complex induced calcium 
signaling with 2-fold greater potency than CTR/RAMP1. These differences in downstream 
signaling are likely due to changes in G-protein coupling efficiency, because overexpression 
of the Gαs subunit enhanced RAMP2-induced amylin binding, whereas Gαs and Gαq 
overexpression enhanced RAMP3-induced amylin binding. 
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The study discussed above showing that CRF1 interacts with RAMP2 also found 
changes in downstream signaling. The coupling efficiency of particular G-protein subunits to 
CRF1 and VPAC2R was altered by co-expression with RAMP1 or RAMP2, compared to the 
receptor expressed alone. Thus, the RAMPs can likely modulate downstream signaling by 
altering the efficiency by which different G-protein subunits couple with their receptors [16], 
a phenomenon termed “functional selectivity.” 
 
RAMPs and receptor trafficking 
In addition to effects on downstream signaling, novel roles for RAMPs in modulating 
receptor trafficking have been identified. The Bouvier laboratory found that RAMPs can 
regulate recruitment of β-arrestins, which are a family of proteins involved in agonist-
mediated GPCR endocytosis and desensitization that can also influence downstream 
signaling [18,19]. Via BRET studies, they observed that agonist- dependent recruitment of β-
arrestin2 to the CLR was dependent the presence of RAMP1 [15]. Other roles specific for 
RAMP3 in receptor trafficking were uncovered in two important studies conducted by the 
Spielman Laboratory. They hypothesized that a PSD-95/Discs-large/ZO-1 homology (PDZ) 
type I domain in the RAMP3 C-terminus but not present in the other RAMPs could facilitate 
protein-protein interactions that would alter receptor trafficking. Typically, the CLR/RAMP 
complex undergoes agonist-stimulated desensitization and subsequent internalization, and 
resensitizes to agonist stimulation very slowly. However, when the CLR/RAMP3 complex is 
co-expressed with N-ethylmaleimide-sensitive factor (NSF), the fate of the complex is 
changed to a recycling pathway, promoting rapid resensitization [20]. The other RAMPs 
could not induce this effect, and point mutations of the RAMP3 C-terminus revealed that it is 
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dependent on an intact RAMP3 PDZ domain. In a subsequent paper, they showed that the 
PDZ domain of RAMP3 can alternatively interact with Na
+
/H
+
 exchanger regulatory factor-1 
(NHERF-1), and this interaction promotes CLR/RAMP3 desensitization and blocks 
internalization [21]. Thus, RAMPs can modulate receptor trafficking through a variety of 
regulatory mechanisms. 
Taken together, these studies reveal that RAMPs can have pleiotropic effects on the 
GPCRs they interact with, ranging from regulation of ligand binding specificity to facilitating 
forward trafficking, modulating downstream signaling, modulating β-arrestin recruitment, 
and altering receptor complex recycling. In addition, there are likely to be many as-yet 
undiscovered receptors that interact with RAMPs, as no large-scale screens for RAMP-
GPCR interactions have been published and molecular determinants of RAMP-GPCR 
interactions have not yet been identified. Thus, a major area of interest in the RAMP field 
remains the identification of novel RAMP-receptor interactions. 
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TABLES 
Table 5-1. Known RAMP-GPCR interactions 
 
Receptor 
Interacting 
RAMPs 
Functional Effects 
of RAMP Interaction 
References 
Calcitonin receptor- 
like receptor 
(CLR) 
RAMP1 
 
RAMP2 
 
RAMP3 
Ligand binding specificity (CGRP) 
 
Ligand binding specificity (AM) 
 
Ligand binding specificity (AM) 
Receptor trafficking 
[2] 
 
[2] 
 
[2] 
[20,21] 
Calcitonin receptor 
(CT) 
RAMP1 
 
 
RAMP3 
Ligand binding specificity (AMY) 
G-protein coupling efficiency 
 
Ligand binding specificity (AMY) 
G-protein coupling efficiency 
[11] 
[17] 
 
[11] 
[17] 
Vasoactive intestinal 
polypeptide/pituitary 
adenylate cyclase-
activating peptide 
receptor 1 
(VPAC1R) 
RAMP1 
 
RAMP2 
 
RAMP3 
? 
 
Downstream signaling 
 
? 
[12] 
 
[12] 
 
[12] 
Glucagon 
receptor 
RAMP2 ? [12] 
Parathyroid hormone 
receptor 1 
(PTHR1) 
RAMP2 ? [12] 
Parathyroid hormone 
receptor 2 
(PTHR2) 
RAMP3 ? [12] 
Calcium sensing 
receptor 
(CSR) 
RAMP1 
 
RAMP3 
? 
 
? 
[13] 
 
[13] 
Secretin receptor 
(SecR) 
RAMP3 ? [14] 
Vasoactive intestinal 
polypeptide/pituitary 
adenylate cyclase-
activating peptide 
receptor 2 
(VPAC2R) 
RAMP1 
 
RAMP2 
 
RAMP3 
G-protein coupling efficiency 
 
G-protein coupling efficiency 
 
? 
[16] 
 
[16] 
 
[16] 
Corticotrophin 
releasing hormone 
factor 1 
(CRF1) 
RAMP2 
G-protein coupling efficiency 
Downstream signaling 
[16] 
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FIGURES 
 
 
Figure 5-1. The RAMP/receptor paradigm for AM and CGRP signaling 
RAMPs convey receptor specificity by heterodimer formation with CLR in the endoplasmic 
reticulum followed by localization to the plasma membrane. 
Adapted from [22] 
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Figure 5-2. BRET technique for the study of RAMP/receptor interactions 
Cells are transfected with the receptor of interest with a Renilla luciferase tag and with the 
RAMP, tagged with yellow fluorescent protein. Cells are then treated with a luciferase 
substrate such as coelanterazine H (CH). A. If the RAMP and receptor do not interact, the 
luciferase will act on the CH and elicit a signal at the luciferase specific wavelength, while 
no signal will be generated from the YFP. B. If, and only if, the RAMP and receptor are 
within about 100 angstroms of each other, indicating an interaction, resonance energy 
transfer can occur from the luciferase tag on the receptor to the YFP tag on the RAMP, 
eliciting a signal at the wavelength specific to YFP. 
  
A. B. 
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Figure 5-3. The pleiotropic effects of RAMPs on GPCRs 
RAMPs interact with numerous GPCRs and can act as receptor chaperones, dictate ligand 
binding specificity, alter G-protein coupling efficiency, and regulate receptor subcellular 
trafficking. 
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Chapter 6: G protein-coupled Receptor 30 Interacts with Receptor Activity Modifying 
Protein 3 and Confers Sex-Dependent Cardioprotection
6,7
 
 
Overview 
Receptor activity modifying protein 3 (RAMP3) is a single pass transmembrane 
protein known to interact with and affect the trafficking of several G protein-coupled 
receptors (GPCRs). We sought to determine whether RAMP3 interacts with G protein-
coupled receptor 30 (GPR30), also known as G-protein estrogen receptor 1 (GPER1). GPR30 
is a GPCR that binds estradiol and has important roles in cardiovascular and endocrine 
physiology. Utilizing bioluminescence resonance energy transfer titration studies, co-
immunoprecipitation, and confocal microscopy, we show that GPR30 and RAMP3 interact. 
Furthermore, the presence of GPR30 leads to increased expression of RAMP3 at the plasma 
membrane in HEK293 cells. In vivo, there are marked sex differences in the subcellular 
localization of GPR30 in cardiac cells, and the hearts of Ramp3
-/- 
mice also show signs of 
GPR30 mislocalization. To determine whether this interaction might play a role in 
cardiovascular disease, we treated Ramp3
+/+ 
and Ramp3
-/- 
mice on a heart disease-prone 
genetic background with G-1, a specific agonist for GPR30. Importantly, this in vivo 
activation of GPR30 resulted in a significant reduction in cardiac hypertrophy and 
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perivascular fibrosis that is both RAMP3- and sex-dependent. Our results demonstrate that 
GPR30-RAMP3 interaction has functional consequences on the localization of these proteins 
both in vitro and in vivo, and that RAMP3 is required for GPR30-mediated cardioprotection. 
 
Introduction 
 Receptor activity modifying proteins (RAMPs), are single-pass, transmembrane 
accessory proteins that interact with G protein-coupled receptors (GPCRs) to modulate their 
trafficking, ligand binding specificity, and downstream signaling. The RAMPs were first 
identified in association with calcitonin receptor-like receptor (CLR) [2,3]—a discovery 
which clarified considerable controversy over CLR function and has since been exploited by 
the pharmaceutical industry for the development of small molecule drugs that specifically 
target the RAMP-CLR interface [4]. Several additional GPCRs have been shown to interact 
with RAMPs [5,6]. Therefore, there remains great interest in understanding the 
pharmacological and biochemical properties of the RAMPs and in continuing to identify 
novel GPCR targets for these proteins, with the ultimate goal of manipulating the RAMP-
GPCR interface for treatment of human disease. 
RAMP3 is unique among the RAMP family members in that it is transcriptionally 
induced by estradiol [7,8] and has been shown to play a sex-dependent role in the 
development of cardiac hypertrophy and transition to heart failure [9]. For these reasons, we 
considered that GPR30, or G protein-coupled estrogen receptor 1 (GPER1), might be a 
candidate RAMP3-binding GPCR. GPR30 binds estradiol with high affinity, eliciting rapid 
intracellular signaling [10,11], and mediates pleiotropic functions in the cardiovascular, 
endocrine, immune, and central nervous systems [12-14]. 
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There is substantial evidence for GPR30-mediated cardioprotection. GPR30 is 
expressed in the rodent and human heart [15,16], and using male rats, Filice et. al. showed 
that GPR30 is involved in mediating the effects of estradiol in the heart [17]. Numerous 
studies have explored the effects of pharmacological activation of GPR30 with G-1, a 
synthetic agonist for GPR30 that specifically activates GPR30 but does not activate the 
steroid estrogen receptors [18]. Administration of G-1 is directly cardioprotective, reducing 
infarct size in rat and mouse hearts exposed to ischemia-reperfusion [15,19]. Furthermore, 
chronic G-1 treatment reduces left ventricular wall thickness and myocyte hypertrophy 
without significant effects on blood pressure or fibrosis in a rat model of salt-induced 
hypertension [20] and attenuates heart failure [21] and diastolic dysfunction independent of 
blood pressure in ovariectomized female rats [22]. Based on these preclinical studies, 
pharmacological activation of GPR30 as a potential therapeutic intervention could have 
utility in the treatment of cardiovascular disease. 
Despite what is known about GPR30, there remains intense controversy regarding the 
trafficking and subcellular localization of GPR30, in addition to many conflicting reports 
regarding its downstream signaling and even ligand binding specificity. Since RAMPs serve 
to modulate these aspects of GPCR behavior, we hypothesized that an interaction with 
RAMPs could potentially clarify some of the controversies surrounding GPR30. Specifically, 
we sought to determine whether RAMP3, an estradiol-induced accessory protein known to be 
important in cardiovascular disease, could interact with and modulate the function of GPR30, 
as an estradiol receptor with protective roles in cardiac and vascular biology.  
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Materials & Methods 
 
Animals 
Ramp3
-/-
 animals were generated as previously described [23] and Ramp3
+/+
 and 
Ramp3
-/-
 mice were crossed to heterozygous RenTgMK mice [9]. Experimental animals were 
8 weeks of age and maintained on an isogenic 129S6/SvEv genetic background. All 
experiments were approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill. 
 
Bioluminescence resonance energy transfer 
BRET titration studies to test the molecular association between GPR30 and RAMP3 
were carried out as previously described [24]. Briefly, the calcium phosphate precipitation 
method was used to transfect HEK293 cells with a constant amount of hGPR30-RLuc, 
hCLR-RLuc (positive control), hB2AR-RLuc, or hD1R-RLuc (negative controls) and 
increasing doses of hRAMP3-YFP. Cells were treated with the luciferase substrate 
coelanterazine H for 10 minutes and read using a Berthold Technologies Mithras LB940 
plate reader. BRET signal was calculated as the ratio of light emitted from YFP (530 nm) to 
light emitted from RLuc (485 nm). Total fluorescence emission was measured at 530 nm 
from wells not treated with coelanterazine H that were excited at 485 nm to control for the 
expression level of hRAMP3-YFP, and total luminescence was determined to control for the 
expression level of the receptors. Results were analyzed using GraphPad Prism. Results 
shown are representative of at least three replicate BRET experiments that were performed 
with similar results. 
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Co-immunoprecipitation 
HEK293 cells were transfected with HA-RAMP3 and FLAG-GPR30 using TransIT-
293 (Mirus) and GPR30 was immunoprecipitated by incubating the cleared cell lysates 
overnight at 4°C with M2 FLAG antibody beads (Sigma-Aldrich). The precipitate was 
washed extensively and sequentially in lysis buffer and in 10 mM Tris-HCl, pH 7.4. For 
immunoblotting, proteins were denatured in SDS-polyacrylamide gel electrophoresis sample 
buffer including 6% β-mercaptoethanol for 30 min at 37°C, fractionated by SDS-
polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, and the 
membrane was blocked for at least 45 min in Tris-buffered saline and 10% nonfat milk. The 
proteins were stained by incubating with rabbit anti-HA antibody (Invitrogen; 1:1000) for 1 h 
at room temperature. Immunoreactive bands were visualized with a chemiluminescence kit 
using anti-rabbit peroxidase-labeled secondary antibody (GE Healthcare) according to the 
procedure described by the supplier (PerkinElmer Life and Analytical Sciences). 
 
Confocal imaging 
HEK293 cells were transfected with HA-RAMP3 and FLAG-GPR30 using TransIT-
293 (Mirus). Transfected cells were grown on glass coverslips coated with poly(D-lysine), 
and then incubated in serum- and phenol red-free media for at least 1 h at 37°C. For live cell 
staining, cells were then incubated in serum- and phenol-free media containing IgG1 
monoclonal anti-HA (1:100; Covance) and IgG2b monoclonal anti-M1 FLAG (1:500; 
Sigma-Aldrich) primary antibodies for 30 min at 37°C. Cells were fixed with 3.7% 
formaldehyde in PBS and permeabilized, then washed with PBS and incubated with anti-
IgG1-488 and anti- IgG2b-568 secondary antibodies (Invitrogen). Alternatively, for dead cell 
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staining, cells were incubated with both primary and secondary antibodies after fixation. 
Cells were also stained with 4',6-diamidino-2-phenylindole (DAPI). Images were collected 
using a Nikon Eclipse confocal fluorescence microscope (Nikon, Tokyo, Japan) and analyzed 
with Nikon EC-Z1 3.90 software. 
 
Gene expression analysis 
mGPR30 and mRamp3 gene expression was analyzed by quantitative reverse 
transcription (RT)-PCR with the Applied Biosystems StepOne Plus machine. The 
primer/probe set for Ramp3 has been previously described [23]. For GPR30, we used a pre-
designed Assay on Demand primer/probe set (#Mm02620446_s1, Applied Biosystems). 
Mouse eukaryotic translation elongation factor 1 alpha 1 was used as the internal control for 
all samples; the primer/probe set has been previously described [9]. RNA was isolated from 
adult tissues with Trizol reagent (Life Technologies) and subsequently DNase treated. Two 
micrograms of total RNA was used to generate cDNA with the MMLV Reverse 
Transcriptase kit (Life Technologies). The delta–delta Ct method was used to determine the 
relative levels of gene expression and shown as a fold increase over wildtype male controls. 
Estrus cycle phase was determined by microscopic examination of mouse vaginal smears 
stained with the Kwik Diff Stain Kit (Thermo Scientific). For the ovariectomized samples, 
mice were 21 to 28 days old at the time of ovariectomy. Mice were anesthetized with avertin 
(0.2-0.4ml/10gm body wt of 1.25% solution) and placed on a warm heating pad to maintain 
body temperature throughout the surgical procedure. Hair was removed from the abdomen 
and a small <1 cm incision was made through the abdominal wall about 1 cm to the left of 
the spinal cord. The ovary was exteriorized and placed on a sterile drape. Silk sutures were 
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used to ligate the oviduct and anterior connective tissue prior to excising the ovary. The body 
wall was then sutured with dissolvable sutures and wound clips were used to close the skin. 
The procedure was repeated on the animal’s right side. Wound clips are removed 4-5 days 
after surgery; 4 weeks later the ovariectomized mice were dissected and the heart tissue was 
used for RT-PCR. 
 
Subcellular fractionation and western blotting 
Homogenized lysates were prepared from heart tissue of Ramp3
+/+
,
 
Ramp3
-/-
,
 
RenTgMK;Ramp3
+/+
, and RenTgMK;Ramp3
-/- 
male and female mice. The nuclear pellet was 
removed by centrifuging at 1300xg for 1 hr. Membrane-enriched fractions of cardiac lysates 
were isolated by subsequent ultracentrifugation at 20,000xg for 1 hr, and the remaining 
supernatant was designated as the cytosolic fraction. Lysates were denatured in SDS-
polyacrylamide gel electrophoresis sample buffer including 6% β-mercaptoethanol for 5 min 
at 100°C, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to a 
nitrocellulose membrane, and the membrane was blocked for 1 hour in casein 
(ThermoScientific). The membrane was stained using rabbit anti-GPR30 primary antibody 
(MBL International) or mouse anti-actin (Sigma-Aldrich) as a loading control, followed by 
goat anti-rabbit 680 or goat anti-mouse 800 secondary antibody (ThermoScientific). 
Membranes were imaged via LI-COR and quantitation of integrated density normalized to 
actin was performed using ImageJ. The student’s T-test was used to compare the ratio of 
plasma membrane to cytosolic GPR30 protein relative to actin and a value of p<0.05 was 
considered statistically significant. Results shown are representative of at least three replicate 
fractionation experiments that were performed with similar results. 
97 
 
G-1 treatment and histology 
Male and female RenTgMK;Ramp3
+/+
 and RenTgMK;Ramp3
-/-
 mice at eight weeks 
of age were anesthetized with avertin (0.2-0.4ml/10gm body wt of 1.25% solution) and 
injected with a subcutaneous, continuous release pellet (Innovative Research of America) 
containing 6 milligrams of G-1 (Tocris) or placebo similar to a previously described method 
[25]. After 40 days of treatment the mice were euthanized. To determine the left ventricle to 
body weight ratio, the heart chambers were dissected and the left ventricle was weighed. 
Subsequently, the left ventricle was fixed in 4% paraformaldehyde and 5 µm sections were 
prepared for staining. Masson’s Trichrome stained slides imaged at 10X were used to analyze 
interstitial and perivascular cardiac fibrosis. Interstitial fibrosis was quantified by blinded 
scoring of the extent of interstitial fibrosis in one representative field per mouse. Perivascular 
fibrosis was quantified by measuring the area of fibrosis surrounding a vessel normalized to 
the vessel lumen area, using ImageJ software. Three vessels were measured per mouse; the 
student’s T-test was used to compare data and a value of p<0.05 was considered statistically 
significant. Cardiomyocyte area was determined by measuring the cross-sectional area of five 
cardiomyocytes in each of two fields per mouse from hematoxylin and eosin (H&E) stained 
slides at 25X, using ImageJ software. The Mann-Whitney test was used to compare data; a 
value of p<0.05 was considered statistically significant. 
 
Blood pressure measurements 
Male and female RenTgMK;Ramp3
+/+
 and RenTgMK;Ramp3
-/-
 mice at 2-5 months of 
age were injected with a subcutaneous, continuous release pellet containing 6 milligrams of 
G-1 or placebo as described above. Blood pressures were measured on unanesthetized mice 
98 
 
using a Coda computerized volume pressure recording tail cuff system (Kent Scientific). 
After a five day period of acclimation to the tail cuff system, blood pressures were measured 
daily for five days on each mouse during the third week following pellet injection. The 
student’s T-test was used to compare data; a value of p<0.05 was considered statistically 
significant. 
 
Results 
To directly test whether GPR30 and RAMP3 interact in living cells, we utilized 
bioluminescence resonance energy transfer (BRET) titration studies [24]. HEK293 cells were 
transfected with a constant dose of hGPR30-RLuc and increasing doses of hRAMP3-YFP. 
We observed a robust increase in the BRET signal with increasing amounts of hRAMP3 
(ΔBRET=0.664), indicating a specific interaction between the two proteins (Figure 6-1A). 
Almost no change in BRET signal was seen with the negative controls, β2-adrenergic 
receptor (ΔBRET=0.061), and Dopamine-1 receptor (ΔBRET=0.079). The positive increase 
in BRET signal observed for hGPR30 and hRAMP3 was an order of magnitude greater than 
the negative controls and comparable to that seen with the positive control, hCLR 
(ΔBRET=0.728). 
To further confirm that hGPR30 and hRAMP3 interact, we performed co-
immunoprecipitation. In cells transfected with either FLAG-hGPR30 alone or with HA-
hRAMP3, we immunoprecipitated with M2-FLAG beads and immunoblotted for HA (Figure 
6-1B). The M2-FLAG beads pull down HA material only when FLAG-hGPR30 and HA-
hRAMP3 are co-expressed, indicating by a second technique that GPR30 and RAMP3 
interact.  
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The ability of GPCRs to enhance the localization of RAMPs in the plasma membrane 
is the standard method in the field by which the association of receptors with RAMPs has 
been tested [6]. Therefore, we imaged the interaction of GPR30 and RAMP3 by confocal 
microscopy of HEK293 cells transiently transfected with HA-hRAMP3 and FLAG-hGPR30 
and stained with epitope-specific antibodies. The top row of Figure 6-2A shows cells stained 
following fixation to identify total cellular proteins. In this representative field, cells are 
present expressing HA-hRAMP3 alone and together with FLAG-hGPR30. When expressed 
alone, diffuse RAMP3 staining occurs throughout the cell. On the other hand, co-expression 
with GPR30 organizes RAMP3 staining and extensive co-localization occurs in the plasma 
membrane and intracellularly on filamentous structures and in puncta. Figure 6-2B shows 
cells stained live and imaged after fixation to identify cell surface proteins. In this 
representative field, cells are present expressing HA-hRAMP3 and FLAG-hGPR30 
individually and together. When expressed alone, RAMP3 is primarily in intracellular 
puncta. On the other hand, co-expression with GPR30 increases the relative amount of 
RAMP3 staining at the cell surface and extensive co-localization occurs. Thus, the formation 
of a GPR30-RAMP3 complex within the cell increases RAMP3 localization to the plasma 
membrane. 
We next sought to determine whether the interaction of GPR30 and RAMP3 has 
functional consequences in vivo. First, we determined the gene expression levels of Gpr30 
and Ramp3 in the hearts of wildtype mice. Expression of both Ramp3 (Figure 6-3A) and 
Gpr30 (Figure 6-3B) was detected in the hearts of male mice, female mice in diestrus and 
estrus, and in female mice who have been ovariectomized to deplete endogenous estradiol. 
For both genes, we observed modest increases in females in estrus compared to diestrus. 
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Ovariectomized females had a statistically significant reduction in both Gpr30 and Ramp3 
expression compared to intact females in diestrus. Though the differences in expression 
between males and females in the phases of the estrus cycle are modest, these findings, 
particularly the reduced gene expression in the ovariectomized females, indicate that cardiac 
Gpr30 and Ramp3 gene expression levels correlate with endogenous estradiol. 
Using heart tissue from Ramp3
+/+
 and Ramp3
-/- 
mice, we investigated GPR30 protein 
levels and localization by performing subcellular fractionation and western blots for GPR30. 
In pooled heart lysates (n=3) from Ramp3
+/+ 
mice, we detected robust expression of GPR30 
protein at the expected molecular size (50 kD) in the membrane fraction and very little in the 
cytosolic fraction (Figure 4A). In contrast, pooled Ramp3
-/-
 heart lysates (n=3) showed 
reduced membrane GPR30 levels (GPR30 integrated density at membrane relative to actin - 
Ramp3
-/- 
= 0.27 compared to Ramp3
+/+
 = 1.0). The Ramp3
-/-
 hearts also show a concomitant 
increase in cytosolic GPR30 protein relative to wildtype (Figure 4A). To determine whether 
cardiac expression and localization of GPR30 protein differs by sex, we performed this same 
experiment using male and female hearts side-by-side. Figure 4B shows the membrane 
fraction from these samples. These data show that Ramp3
+/+
 hearts have more membrane-
localized GPR30 than Ramp3
-/-
 hearts in both sexes. Furthermore, female hearts have more 
overall GPR30 at the membrane compared to males, a difference that was statistically 
significant for wildtype animals (relative GPR30 integrated density at membrane - females: 
Ramp3
+/+ 
= 1.0, Ramp3
-/-
 = 0.43; males: Ramp3
+/+ 
= 0.41, Ramp3
-/-
 = 0.10). 
To explore the effect of RAMP3 on GPR30 localization in the setting of 
cardiovascular disease, we utilized RenTgMK mice. The RenTgMK mouse is a well-
described model of angiotensin II-mediated chronic hypertension and cardiac hypertrophy 
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[26-28]. We have previously shown that Ramp3 gene expression is increased in the hearts of 
RenTgMK mice of both sexes compared to wildtype, and this heart disease-related 
upregulation of Ramp3 is greatest in females [9]. For the current study, we generated 
RenTgMK mice lacking Ramp3 (RenTgMK;Ramp3
-/-
) and RenTgMK mice with intact 
RAMP3 (RenTgMK;Ramp3
+/+
), isolated heart tissue, and performed subcellular fractionation 
and western blotting to determine GPR30 localization in this model of heart disease. 
Consistent with our findings in wildtype animals, we detected more GPR30 protein at the 
membrane in RenTgMK females than in males (relative GPR30 integrated density at 
membrane - females = 1.0; males = 0.58) (Figure 4C). Using replicate samples, we also 
observed that RenTgMK;Ramp3
-/- 
mice had reduced GPR30 at the plasma membrane 
compared to RenTgMK;Ramp3
+/+
 mice (relative GPR30 integrated density at membrane - 
RenTgMK;Ramp3
+/+
 = 1.0; RenTgMK;Ramp3
-/-
 = 0.29) (Figure 4D). Figure 4E summarizes 
the quantitative findings and statistical analysis from each of these experiments. For both 
sexes, there is a robust trend of reduced membrane to cytosolic (P:C) ratio of GPR30 protein 
in disease-free and RenTgMK hearts in the absence of Ramp3. Female mice have a higher 
P:C ratio of GPR30 protein compared to males across all conditions, and this sex difference 
is statistically significant in Ramp3
+/+
 and RenTgMK;Ramp3
+/+
 hearts. Thus, female mice 
have significantly increased membrane-localized GPR30 protein compared to males, and 
there is a trend of GPR30 protein mislocalization in male and female Ramp3
-/- 
and 
RenTgMK;Ramp3
-/-
 heart tissue. 
 Finally, we investigated whether pharmacological activation of GPR30 is 
cardioprotective in the RenTgMK model of heart disease, and whether these effects are 
dependent on RAMP3. We treated male and female RenTgMK;Ramp3
+/+
 and 
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RenTgMK;Ramp3
-/- 
mice with G-1, the specific agonist for GPR30, or a placebo for a period 
of 40 days and then performed cardiovascular phenotyping. First, we measured blood 
pressure to determine whether G-1 treatment affected the hypertensive phenotype of the 
RenTgMK mice. We found no significant change in blood pressure with G-1 treatment in 
male (RenTgMK;Ramp3
+/+
 placebo = 145.6 ± 22.4 mmHg, RenTgMK;Ramp3
+/+
 G-1 = 148.7 
± 25.9 mmHg;  RenTgMK;Ramp3
-/-
 placebo = 150.3 ± 38.6 mmHg, RenTgMK;Ramp3
-/-
 G-1 
= 159.5 ± 25.1 mmHg) or female mice (RenTgMK;Ramp3
+/+
 placebo = 128.5 ± 25.6 mmHg, 
RenTgMK;Ramp3
+/+
 G-1 = 118.0 ± 25.0 mmHg;  RenTgMK;Ramp3
-/-
 placebo = 135.8 ± 
27.4 mmHg, RenTgMK;Ramp3
-/-
 G-1 = 140.1 ± 38.8 mmHg). 
Next, we examined cardiac fibrosis. Consistent with other studies [20], we found that 
there were no overt differences in interstitial fibrosis between the genotypes or with G-1 
treatment in male mice (Figure 6-5A and B). However, G-1 treatment did result in a 
statistically significant reduction in perivascular fibrosis (Figure 6-5C and D) in the hearts of 
RenTgMK;Ramp3
+/+
, but not RenTgMK;Ramp3
-/-
, male
 
mice. We also examined female 
hearts and found no significant differences in either perivascular or interstitial fibrosis. 
We also found interesting changes in the left ventricle to body weight (LV:BW) ratio 
of these mice. The LV:BW ratio of RenTgMK;Ramp3
+/+
 male mice was significantly 
reduced with G-1 treatment compared to placebo (Figure 6-6A). RenTgMK;Ramp3
-/- 
males, 
on the other hand, had no reduction in their left ventricle to body weight ratio with G-1 
treatment. Female mice of both genotypes had no significant response to G-1 treatment. 
Body weights did not differ by genotype or treatment condition for males 
(RenTgMK;Ramp3
+/+
 placebo = 24.36 ± 4.19 g, RenTgMK;Ramp3
+/+
 G-1 = 23.79 ± 2.98 g;  
RenTgMK;Ramp3
-/-
 placebo = 23.19 ± 2.73 g, RenTgMK;Ramp3
-/-
 G-1 = 23.96 ± 3.39 g) or 
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females (RenTgMK;Ramp3
+/+
 placebo = 18.44 ± 1.60 g, RenTgMK;Ramp3
+/+
 G-1 = 19.23 ± 
2.21 g;  RenTgMK;Ramp3
-/-
 placebo = 20.05 ± 1.77 g, RenTgMK;Ramp3
-/-
 G-1 = 20.15 ± 
1.75 g). In addition to determining LV:BW ratios, we measured cardiomyocyte cross-
sectional area, which revealed results consistent with the heart weight findings. Only male 
RenTgMK mice with intact Ramp3 showed a significant reduction in cardiomyocyte area 
with G-1 treatment, while females or males lacking Ramp3 did not respond to G-1 treatment 
(Figure 6-6B and C).  
 
Discussion 
The identification of novel GPCR-RAMP interactions is of great interest because this 
complex forms a pharmacologically tractable interface, which could potentially be 
manipulated for the treatment of human disease [4].  In the current study, we identify GPR30, 
an estradiol receptor with important functions in the cardiovascular system [12-14], as a 
novel target for RAMP3, a modifying protein also known for its sex-dependent 
cardioprotective effects [9]. The association of GPR30 with a RAMP is of particular interest 
because this has the potential to clarify much of the controversy that still surrounds GPR30’s 
cellular localization, ligand-binding, and function. Furthermore, GPR30 is the first class I 
GPCR to be shown to interact with a RAMP.  
In the present study, we have made use of both standard and newly available 
techniques in the field to provide compelling evidence for the GPR30-RAMP3 interaction. 
Bioluminescence resonance energy transfer, already well-described for its utility in testing 
protein-protein interactions in general, has recently been used as an elegant and quantitative 
method to interrogate GPCR-RAMP interactions [6,24]. Here, we use this method to reveal a 
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robust interaction between GPR30 and RAMP3 that is equivalent to that observed with CLR, 
the canonical RAMP-associated receptor. Co-immunoprecipitation of the epitope tagged 
GPR30 and RAMP3 proteins further supports this conclusion. In the past, the use of confocal 
microscopy to test the ability of GPCRs to enhance the localization of RAMPs in the plasma 
membrane was the standard method by which the association of receptors with RAMPs had 
been tested [6]. Similarly, with this technique, we found that GPR30 and RAMP3 colocalize, 
and expression of GPR30 enhances RAMP3 localization to the cell surface. This provides 
further evidence for an interaction between the two proteins, and shows that the association 
of GPR30 and RAMP3 alters the localization of this complex. 
In addition to the localization effects observed in vitro, RAMP3 may also affect 
localization of GPR30 in vivo, as absence of RAMP3 results in a trend of mislocalized 
GPR30 in both normal mouse heart tissue and in heart tissue on a background of 
cardiovascular disease. Sex-differences in GPR30 localization were also observed, as the 
hearts of female mice have a significantly increased proportion of GPR30 protein at the 
plasma membrane compared to males when Ramp3, an estrogen regulated gene, is present. 
Most importantly, this in vivo effect has functional consequences, since pharmacological 
activation of GPR30 reduces cardiac hypertrophy and perivascular fibrosis in male mice with 
intact Ramp3, while genetic loss of Ramp3 eliminates this cardioprotective effect. These 
effects were independent of blood pressure, which is consistent with previous studies 
showing that chronic G-1 treatment does not affect blood pressure under hypertensive 
conditions in intact male or female rats [20,22,29,30]. Thus, it is likely that this 
cardioprotection is due to direct effects of GPR30-RAMP3 function in the heart, which is 
influenced by the localization of the protein complex. 
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Interestingly, we found that the reduction of cardiac hypertrophy and perivascular 
fibrosis is only observed in male mice, indicating that protective effect of GPR30 in the heart 
is both RAMP3- and sex-dependent. Our previously published work has demonstrated that 
RenTgMK;Ramp3
-/-
 males at 5-6 months of age have exacerbated cardiac hypertrophy. We 
intentionally performed our cardiovascular phenotyping experiments in mice beginning at 2 
months of age, and as expected at this early time point, the LV:BW ratios and cardiomyocyte 
areas did not differ in mice lacking Ramp3. Thus, Ramp3 genotype-dependent effects do not 
confound the interpretation of our results from the G-1 treatment experiments.  Figure 6-7 
models our proposed explanation for why the effectiveness of G-1 treatment was dependent 
on sex and Ramp3 genotype. We hypothesize that because female mice have increased 
GPR30 at the cell membrane compared to males and high levels of the endogenous GPR30 
ligand, estradiol, they remain cardioprotected even when Ramp3 is absent, regardless of G-1 
treatment. However, males have reduced membrane GPR30 and low estradiol levels. This 
leads to a worsened cardiovascular phenotype that can be ameliorated with G-1 treatment 
only if the males express Ramp3, which may maintain GPR30 localization at the cell 
membrane, allowing for efficient response to ligand treatment. The requirement of intact 
Ramp3 for GPR30 cardioprotection may also depend on RAMP-mediated effects in addition 
to localization, such as downstream signaling. Future studies will be directed at determining 
whether and how RAMP3 alters GPR30-mediated cell signaling. 
Our results are consistent with our previous studies showing a sex-dependent 
cardioprotective role for RAMP3 [9], and our findings also complement studies by others 
including Jessup et. al. showing that G-1 treatment significantly reduces cardiomyocyte 
hypertrophy in intact females rats with salt-sensitive hypertension [20]. Though G-1 
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treatment reduces interstitial fibrosis in ovariectomized female rats [21,22], the reduction in 
perivascular fibrosis with G-1 treatment in male mice shown here is unique. To our 
knowledge, this is the first report of GPR30 agonist-induced cardioprotection in a genetic 
mouse model of cardiovascular disease, with the additional discovery of sex differences. The 
requirement for RAMP3 to mediate these effects is entirely novel. 
Our results demonstrate for the first time that GPR30 and RAMP3 interact. This 
interaction has functional consequences on the localization of these proteins both in vitro and 
in vivo, and we show that RAMP3 plays a critical and sex-dependent role in GPR30-
mediated cardioprotection.  GPR30-RAMP3 is a novel pathway that may contribute to sex 
differences in cardiovascular disease susceptibility and progression, and ultimately, this 
pathway could potentially be targeted for sex-tailored treatment for cardiovascular disease. 
  
107 
 
FIGURES 
 
 
 
 
 
Figure 6-1. In vitro analysis of GPR30-RAMP3 protein-protein interaction  
A. BRET analysis of the hGPR30-hRAMP3 interaction. hGPR30+hRAMP3 (blue) shows a 
robust increase in BRET signal with increasing doses of hRAMP3-YFP, as does the positive 
control, hCLR+ hRAMP3 (green). The negative controls, B2-adrenergic receptor (hβ2AR, 
red), and Dopamine-1 receptor (D1R, black), which are not expected to interact with 
RAMPs, show negligible change in the BRET signal. Results shown are representative of at 
least three replicate experiments that were performed with similar results. B. 
Immunoprecipitation with M2 FLAG  beads and immunoblotting with anti-HA primary 
antibody. M2 FLAG pulls down HA immunoreactivity specifically when FLAG-hGPR30 
and HA-hRAMP3 are  co-expressed. Non-specific bands at 25 and 50 kDa are IgG bands. 
The experiment was repeated three times with similar results. 
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Figure 6-2. Localization of GPR30 and RAMP3 in vitro  
A. Fixed Cell Staining - Confocal microscopy of HEK293 cells transfected with HA-
hRAMP3 (green in merged panel) and FLAG-hGPR30 (red in merged panel) stained fixed 
with M1 FLAG antibody and anti-HA antibody and then with secondary antibody. Left panel 
shows the FLAG-hGPR30 channel alone, the middle panel shows the HA-hRAMP3 channel 
alone (arrow indicates a cell expressing only HA-hRAMP3), and the right panel shows the 
two channels merged with DAPI nuclear stain in blue (arrow indicates a cell expressing both 
FLAG-hGPR30 and HA-hRAMP3). B. Live Cell Staining - HEK293 cells were similarly 
transfected and stained live with M1 FLAG antibody and anti-HA antibody followed by 
fixing and staining with secondary antibody. The left panel shows the FLAG-hGPR30 
channel alone (arrow indicates a cell expressing only FLAG-hGPR30, the middle panel 
shows the HA-hRAMP3 channel alone (arrow indicates a cell expressing only HA-
hRAMP3), and the right panel shows the two channels merged with DAPI nuclear stain in 
blue (arrow indicates a cell expressing both FLAG-hGPR30 and HA-hRAMP3). The regions 
indicated by the white box are enlarged in the corresponding panels below and arrows 
indicated colocalization at the plasma membrane. The experiment was repeated three times 
with similar results. 
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Figure 6-3. Cardiac expression of Gpr30 and Ramp3 
Quantitative PCR was used to compare the expression of A. Ramp3 and B. Gpr30 in the 
hearts of male mice, female mice in estrus or diestrus, and ovariectomized (Ovx) females; 
n=3-4 animals per group. Depletion of endogenous estradiol by ovariectomy in female mice 
results in a statistically significant reduction in expression of both Ramp3 and Gpr30 in the 
heart. 
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Figure 6-4. Localization of GPR30 and RAMP3 in vivo  
(A-D) GPR30 immunoblots of fractionated cardiac lysates. Membrane-enriched and 
cytosolic fractions were prepared by ultracentrifugation and western blotting for GPR30 
protein was performed. The integrated density of GPR30 normalized to actin for each lane is 
listed below each blot, with the first lane set equal to 1.0. (A) GPR30 western blot of cardiac 
lysates of Ramp3
+/+
 and Ramp3
-/-
 mice (n=3 animals per genotype). GPR30 is reduced in the 
membrane fraction and increased in the cytosolic fraction in Ramp3
-/-
 versus Ramp3
+/+ 
hearts. 
(B) GPR30 western blot of the plasma membrane fraction of cardiac lysates from male and 
female Ramp3
+/+
 and Ramp3
-/-
 mice (n=3 animals per group). Females have more membrane-
localized GPR30 than males, and loss of Ramp3 reduces membrane GPR30 levels in both 
sexes. (C) Western blot of the plasma membrane (P) and cytosolic (C) fractions of pooled 
RenTgMK male and female hearts (n=3 animals per group). In this heart disease model, 
females have increased membrane-localized GPR30 compared to males. (D) Western blot of 
the plasma membrane (P) and cytosolic (C) fractions of cardiac lysates from replicate 
samples of RenTgMK;Ramp3
+/+
 (n=3) and RenTgMK;Ramp3
-/-
  (n=3) mice. Each replicate 
number represents a separate animal. The average densities for the P and C fraction for each 
genotype are listed below the blot. Loss of Ramp3 on the RenTgMK background reduces 
plasma membrane GPR30. (E) Quantitation of immunoblot data showing the normalized 
ratio of GPR30 protein in the plasma membrane and cytosolic fractions (P:C) in males and 
female hearts across genotypes. Ramp3
+/+
 and RenTgMK;Ramp3
+/+
 females have 
significantly higher GPR30 P:C ratios compared to males of the same genotype. Numbers 
inside bars represent n for each group, numbers above bars represent the average P:C ratio 
for each group; * = p<0.05.  
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Figure 6-5. The effect of in vivo activation of GPR30 on cardiac fibrosis  
A. Masson’s Trichrome staining of interstitial fibrosis in the left ventricle of male 
RenTgMK;Ramp3
+/+
 and RenTgMK;Ramp3
-/-
 mice treated with 6 mg continuous release 
pellets of G-1 or placebo for 40 days, B. with quantitation. No overt differences in interstitial 
fibrosis were observed between the genotypes or with G-1 treatment. C. Masson’s Trichrome 
staining of perivascular fibrosis in the left ventricle of male RenTgMK;Ramp3
+/+
 and 
RenTgMK;Ramp3
-/-
 mice treated with G-1 or placebo, D. with quantitation. G-1 treatment 
resulted in a statistically significant reduction in perivascular fibrosis in RenTgMK;Ramp3
+/+
 
males, but not in RenTgMK;Ramp3
-/-
 males or female mice of either genotype. N=5-9 
animals per group.  
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Figure 6-6. The effect of in vivo activation of GPR30 on left ventricular hypertrophy  
A. Left ventricle to body weight (LV:BW) ratios of male and female RenTgMK;Ramp3
+/+
 
and RenTgMK;Ramp3
-/-
 mice treated with the G-1 or placebo. Male RenTgMK;Ramp3
+/+
 
mice show a statistically significant reduction in LV:BW ratio with G-1 treatment (p<0.05). 
B. Hematoxylin and eosin staining of the left ventricles of male and female 
RenTgMK;Ramp3
+/+
 and RenTgMK;Ramp3
-/-
 mice. C. Cardiomyocyte cross-sectional area 
measurements of male and female RenTgMK;Ramp3
+/+
 and RenTgMK;Ramp3
-/-
 mice. Male 
RenTgMK;Ramp3
+/+
 mice show a statistically significant reduction in cardiomyocyte area 
with G-1 treatment (p<0.001). N=5-9 animals per group.  
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Figure 6-7. A model of GPR30- and RAMP3-mediated cardioprotection 
Female mice have increased GPR30 at the cell membrane compared to males and high levels 
of the estradiol. Therefore, regardless of G-1 treatment, females may remain cardioprotected 
even when Ramp3 is absent. Males have reduced membrane GPR30 and low estradiol levels, 
and thus lack the natural cardioprotection seen in females. G-1 treatment can improve the 
cardiovascular phenotype only if the male expresses Ramp3, which may maintain GPR30 
localization at the cell membrane, allowing for efficient response to ligand treatment. 
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Chapter 7: Conclusions and Future Directions 
 
Summary of Results 
 We have shown that the estrogen GPCR, GPR30, is a novel receptor partner for 
RAMP3. BRET and co-immunoprecipitation studies confirm that GPR30 and RAMP3 
interact in vitro. Confocal microscopy of cells expressing epitope-tagged versions of GPR30 
and RAMP revealed that GPR30 and RAMP3 co-localize, and co-expression with GPR30 
increases plasma membrane expression of RAMP3. This finding is consistent with the 
standard assay in the field for identifying RAMP-GPCRs, discussed in Chapter 5, which is to 
test the ability of a GPCR to translocate a RAMP to the plasma membrane [1].  
Both Gpr30 and Ramp3 are expressed at slightly higher levels in the hearts of female 
mice than in males. The hearts of ovariectomized females also show a significant reduction 
in Gpr30 and Ramp3 expression compared to intact females in diestrus, indicating that the 
expression of these proteins is, to some extent, regulated by endogenous estrogen. We also 
found that GPR30 protein is mislocalized in the hearts of male and female Ramp3
-/-
 mice, 
both under unstressed conditions and in the setting of cardiovascular disease.  
Importantly, we found that pharmacological activation of GPR30 is cardioprotective 
in a RAMP3- and sex-dependent fashion. Treatment with the GPR30 agonist G-1 in male 
mice with intact RAMP3 resulted in reduced LV:BW ratio, cardiomyocyte area, and 
perivascular fibrosis. These effects were independent of blood pressure, as G-1 treatment did 
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not significantly affect blood pressure in any of our treatment groups. Interestingly, the 
cardiovascular phenotype of male mice lacking RAMP3 and female mice of either genotype 
was not ameliorated with GPR30 activation. This indicates that GPR30 requires RAMP3 to 
mediate its protective effects on the heart. We hypothesize that female mice do not respond 
to G-1 treatment because their higher endogenous levels of RAMP3, GPR30, and estradiol 
likely lead to enhanced cardioprotection relative to males, regardless of agonist treatment.  
Taken together, these results identify a new receptor partner for the RAMP family, 
GPR30. GPR30 is the first class I GPCR to be shown to interact with the RAMPs. All 
previously identified RAMP-interacting receptors are from class II [1-4], with the exception 
of calcium sensing receptor [5], which is a class III GCPR. These studies also shed new light 
on a molecular mechanism that may be involved in estrogen-mediated cardioprotection.  
 
Current State of the Field – GPR30, RAMP Biology, and Cardiovascular Disease 
 The work presented here adds to our understanding of RAMP-receptor interactions 
and highlights the role of one such interaction in a model of cardiovascular disease. There are 
numerous areas relating to these topics that are being actively pursued, a few of which are 
highlighted here. 
 
GPR30 receptor pharmacology 
 The trafficking network, downstream signaling pathways, and cellular functions of 
GPR30 are still largely unresolved and remain contested in the field of GPR30. One of the 
most contentious properties of GPR30 is related to its subcellular location. GPR30 was 
originally detected in the endoplasmic
 
reticulum of Cos-7 cells transfected with GPR30-GFP 
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[6]. Subsequently, two other groups localized GPR30 to the
 
plasma membrane using HA-
GPR30 transfected HEK-293 cells and FLAG-GPR30 transfected HeLa cells [7,8]. More 
recently, Dr. Leeb-Lundberg’s group has found that GRP30 associates with cytokeratin-
containing intermediate filaments throughout the cytoplasm [9]. Finally, exposure to estradiol 
can cause translocation of GPR30 to the plasma membrane one hour after treatment [8]. 
Indeed, this controversy over the subcellular localization of GPR30 was what first inspired 
our hypothesis that GPR30 could interact with RAMPs, as this confusion in the field was 
very reminiscent of the state of the field of CLR research, prior to the discovery of the 
RAMPs. Our study investigating the interaction of GPR30 and RAMP3 has shed some light 
on this subject, indicating that for both GPR30 and RAMP3, localization to the plasma 
membrane is enhanced by co-expression of these two proteins compared to when they are 
expressed alone. Additionally, we are not the only laboratory to investigate possible 
trafficking partners for GPR30. An interesting recent study by Akama et. al. found that 
GPR30 interacts with post-synaptic density (PSD)-95, a scaffolding protein, via its PDZ 
binding motif. This interaction increased localization of GPR30 to the plasma membrane in 
Cos-7 cells [10]. These recent discoveries are beginning to provide some clarification of 
GPR30’s cellular localization, but it is evident that there still much to learn about how the 
results of these different studies fit into the bigger picture of GPR30 trafficking. 
 The downstream pathways by which GPR30 signals are another source of confusion. 
Activation of GPR30 by estrogen or the specific synthetic agonist, G-1, has been shown to 
elicit multiple rapid intracellular responses including calcium mobilization [11], activation of 
adenylyl cyclase [12], ERK1/2 [12,13] and AKT [14], but these downstream signaling events 
are not consistent among studies and vary widely depending on cell type, ligand type, and 
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ligand dosage. Further complicating the picture, in some cellular contexts, GPR30 also 
appears to exhibit high levels of constitutive activity [15]. Though we in the Caron 
Laboratory have not yet published results pertaining to GPR30 signaling, RAMPs do have 
well-described roles in modulating GPCR downstream signaling [3,4]. It will be important to 
take into account possible roles of RAMP3 in modulating GPR30 signal in our own future 
studies and within the field of GPR30 research in general. 
 The controversy over GPR30 pharmacology does not end with questions about its 
trafficking and signaling. Indeed, growing evidence supports the fact that GPR30 can 
actually bind to multiple endogenous and exogenous ligands. Multiple reports have 
confirmed that GPR30 binds to estrogen with high affinity (Kd≈3–7 nM) [6,16,17]. However, 
unlike most GPCRs which typically bind a single ligand, recent studies have shown that 
GPR30 can also mediate the vascular functions of another steroid hormone, aldosterone [18-
20]. Numerous phytoestrogens (estrogenic compounds synthesized by plants) and 
xenoestrogens (synthetic estrogenic compounds) including genistein, certain pesticides, and 
bisphenols, though traditionally thought to act through ERα or ERβ, can also bind to GPR30 
[21]. Given that one of the major effects of RAMPs on GPCRs is the modulation of ligand-
binding specificity [2,22], the possible role of the RAMP family in regulating GPR30’s 
ability to bind to its multiple ligands will be of great interest in the field moving forward. 
 
The cardioprotective effects of GPR30 and RAMP3 
Though we are the first to show the interaction between the two, our work on GPR30 
and RAMP3 builds upon an existing body of knowledge supporting the notion that these 
proteins have cardioprotective effects. The protective role of GPR30 in the heart has been a 
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major focus area in the GPR30 research field. High levels of GPR30 are detected in normal 
and diseased human arteries [13] and arterial blood vessels in the rat and mouse [23]. 
Additionally, activation of GPR30 by G-1 has vasodilator effects in isolated rodent and 
human arterial blood vessels [24], acutely depresses blood pressure in normotensive rats, 
blocks stimulated proliferation of human vascular smooth muscle cells [11] and is directly 
cardioprotective with ischemia/reperfusion challenge in isolated rat and mouse hearts 
[25,26]. In addition, one model of genetic deletion of GPR30 results in sex-dependent 
changes in basal blood pressure [27]. 
A few in vivo studies of GPR30 activation have also been carried out recently in 
rodent models of cardiovascular disease, in addition to our own. In 2010, Jessup et. al. 
showed that chronic G-1 treatment significantly reduces cardiomyocyte hypertrophy in intact 
female rats with salt-sensitive hypertension [28]. A second study by the same group in 2012 
showed that G-1 treatment preserved diastolic cardiac function and reduced left ventricular 
remodeling in ovariectomized female rats [29]. Kang et al. have also found that chronic G-1 
treatment attenuates heart failure in ovariectomized, isoproterenol-treated female rats [30]. 
Each of these studies support the notion that GPR30 signaling is cardioprotective, and this is 
complemented by our results as well. Our finding that G-1 protects the heart in males is 
novel, and to our knowledge is the first study utilizing chronic G-1 treatment in a genetic 
mouse model for the study of cardiovascular disease. 
Similarly, within the RAMP family, RAMP3 has several unique features which argue 
for a protective role in cardiovascular disease. In the unstressed heart, RAMP3 is only 
detected at low levels, while RAMP2 is highly expressed [31]. However, numerous studies 
including our own demonstrate that under conditions of cardiovascular stress, inflammation, 
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hypoxia, or oxidative stress, the expression of RAMP2 is markedly downregulated with a 
concomitant and robust upregulation of RAMP3 gene expression [32-37]. This dynamic 
“RAMP2/3 switch” has suggested that RAMP3 may impart a different effect than RAMP2 
on GPCR targets in the setting of heart disease. Newer studies have similarly found that 
RAMP3 expression is increased in failing rat cardiomyocytes [38], and inhibition of nitric 
oxide increases RAMP3 expression in a rat model of cardiac hypertrophy [39] and 
hypertension [40]. 
Also of interest to the study of cardiovascular disease, RAMP3 is potently induced by 
estrogen in mice [41] and contains functional estrogen receptor response elements in its 
promoter [42]. This indicates that RAMP3 may also have sex-dependent roles of potential 
importance in cardiovascular disease. A recent publication by the Caron Laboratory, 
mentioned briefly in Chapter 6, has brought together the idea of RAMP3’s cardioprotective 
and sex-dependent roles. We found that genetic loss of Ramp3 exacerbated the progression to 
heart failure in our RenTgMK mouse model [43]. Thus, RAMP3 has a protective effect in the 
heart, as has long been hypothesized. This effect was dependent upon on sex, as only male 
mice transition to heart failure when lacking Ramp3. The results presented in Chapter 6 build 
on this finding, further supporting the concept that RAMP3, via its interaction with GPR30, 
is cardioprotective in a sex-dependent fashion. 
 
RAMP biology 
 The major known roles of the RAMP family are discussed in detail in Chapter 5. To 
date, published studies have discovered nine class II GPCRs and one class III GPCR that 
interact with one or more members of the RAMP family. Our results presented in Chapter 6 
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identifies GPR30 as the eleventh receptor overall and the first class I GPCR to interact with a 
RAMP. This family of accessory proteins is known to regulate GPCR translocation to the 
plasma membrane, ligand binding specificity, subcellular trafficking, G-protein coupling 
efficiency, β-arrestin coupling, and downstream signaling, and their physiological importance 
has been described through the use of genetic mouse models [44]. Though our knowledge of 
the RAMPs is growing, there is still much to learn. 
One point worth noting is that most published data on RAMP-receptor interactions 
actually show translocation of the RAMP to the cell surface in the presence of the receptor 
and not the translocation of the receptor itself (with the exceptions of CLR [45], CSR [5], and 
CRF1 [4]). While this is currently the standard assay in the field, it is important to recognize 
that numerous RAMP-interacting receptors do not necessarily require the RAMP to reach the 
cell surface, while the RAMP does apparently require an interacting receptor to reach the cell 
surface. In fact, it may be more appropriate to consider that the receptors translocate the 
RAMPs, rather than the other way around. 
Furthermore, our study on RAMP3 and GPR30, as well as the Sexton Laboratory’s 
study on RAMP3 and SecR [1] are the only published manuscripts that have utilized the 
BRET technique to identify new RAMP-receptor interactions, while nearly all previously 
published studies relied on confocal microscopy showing translocation of the RAMP to the 
cell surface in the presence of the receptor to define an interaction. We anticipate that this 
may signal a needed shift in the field toward the use of more robust and quantitative methods 
to identify novel receptor partners for the RAMP family. 
As discussed previously, the receptors known to bind RAMPs and the effects of 
RAMP binding are summarized in Table 5-1. A major gap in our knowledge of RAMP-
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receptor interactions is with regard to the functional effects of these interactions. As Table 5-
1 clearly demonstrates, the consequences of RAMP interactions, both biochemically and 
physiologically, remain unknown for the majority of the described RAMP-interacting 
receptors. If we are to gain a comprehensive view of the importance of RAMP-GPCR 
interactions, future studies should aim to clarify these effects. 
In addition to deepening our understanding of the effects of RAMP-receptor 
interactions, a major goal in the field of RAMP research is to continue identifying novel 
RAMP-interacting receptors. Since no comprehensive screening of GPCRs for the ability to 
bind RAMPs has been published, it stands to reason that there are likely numerous additional 
receptors that interact with RAMP family members that have yet to be identified. A major 
reason for the interest in finding new receptor partners for the RAMPs is that these 
interactions may represent future pharmacological targets. More than 50% of all clinically 
available drugs target GPCRs [46], and currently, compounds targeting the CLR/RAMP1 
interface developed by Merck and Boehringer Ingelheim are in clinical trials for the 
treatment of migraine [47-49]. Thus, there is great interest in understanding pharmacological 
and biochemical properties of the RAMPs and their receptor partners, with the ultimate goal 
of manipulating the RAMP/GPCR interface for the treatment of human disease [50,51]. 
 
Future Directions 
 While we have learned much so far about the interaction of GPR30 and RAMP3, 
there are many studies planned for the future of this project that aim to broaden our 
understanding of the pharmacological and pathophysiological significance of the GPR30-
RAMP interaction. 
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Future studies pertaining to GPR30 ligand binding and downstream signaling 
A major future direction for this project will be to directly test the hypothesis that the 
interaction of GPR30 with the RAMPs dictates differential ligand binding specificity and 
downstream signaling of GPR30 for its currently identified steroid ligands. As discussed 
earlier, GPR30 has been shown to bind to multiple ligands, and the RAMPs may be involved 
in dictating which of these ligands GPR30 binds to under different circumstances. Chapter 6 
focuses specifically on our characterization of the GPR30/RAMP3 interaction, but our 
preliminary data also shows that GPR30 can actually bind RAMP1 and RAMP2, as well 
(Figure 7-1). To test the hypothesis that RAMP interactions may influence GPR30 ligand 
binding specificity, future studies can make use of HEK293 cells transfected with GPR30 
with or without each of the three RAMPs. Using standard filtration-based, radioreceptor 
assay methods [52], the relative binding specificity of estrogen, aldosterone, and possibly 
phytogestrogens to GPR30 in the presence and absence of each of the three RAMPs could be 
determined. We expect GPR30 alone to show high-affinity binding to estrogen, based on 
previously published studies, and we predict that this binding may be enhanced in the 
presence of one or more of the RAMPs. It is important to note that radio-labeled binding of 
aldosterone to GPR30 has not yet been formally demonstrated, and so the addition of 
RAMPs to these assays may be highly revealing. Based on the effects of RAMPs on the 
ligand binding characteristics for other GPCRs, it is probable that different RAMPs will 
impart GPR30 with different relative affinities for ligand binding. Therefore, we could also 
perform “cold” ligand competition experiments in which the relative affinities for different 
GPR30 ligands can be compared in the presence of the different GPR30-RAMP complexes. 
126 
 
Future studies of GPR30-RAMP pharmacology should also focus on downstream 
signaling. Based on known roles for the RAMPs, we expect that RAMPs will influence the 
downstream signaling properties of GPR30. We have already attempted to interrogate 
GPR30 signaling with and without RAMP3 by a variety of methods. Early studies in the 
GPR30 field showed that GPR30 can signal through cyclic AMP [53]. Therefore, we utilized 
EPAC (exchange protein activated by cAMP)-based BRET studies to determine whether 
GPR30 does in fact signal through cAMP, and whether this is altered by RAMP3. Results 
from these studies, repeated on multiple occasions with both G-1 and estrogen as the ligand, 
showed that GPR30 did not activate cAMP, regardless of RAMP3 (Figure 7-2A). We also 
utilized forskolin to induce cAMP, and found that GPR30 activation also did not inhibit 
cAMP. Studies have further shown that GPR30 can signal through the MAPK pathway 
[13,53], so we also tested ERK phosphorylation downstream of GPR30. Numerous western 
blot experiments performed to address this question failed to generate a clear conclusion. The 
most consistent result observed was that in many experiments, co-expression of GPR30 and 
RAMP3, and sometimes expression of GPR30 alone, in HEK293 cells often lead to a basal 
increase in ERK phosphorylation compared to RAMP3 alone or empty vector (Figure 7-2B). 
However, no consistent response to ligand treatment was observed across experiments (G-1, 
estrogen, aldosterone, and ICI 182,780 were all tested). Generation of a stably expressing 
GPR30 HEK293 cell line did not improve outcomes in response to signaling, but did 
recapitulate the finding that basal pERK was increased (Figure 7-2C). We also utilized an 
ELISA for detection of total and phosphorylated ERK (Invitrogen) to address the question of 
GPR30 downstream signaling, but technical problems with the assay standard curve limited 
the utility of these results. Lastly, mouse embryonic fibroblasts were isolated from wildtype 
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and Ramp3
-/-
 mice at e18.5, and we treated these cells with G-1 or estrogen to again observe 
downstream signaling. Similar to our HEK293 experiments, no response to ligand was 
observed in wildtype MEF cells, despite the fact that the MEFs do express GPR30 protein. 
However, increased basal phosphorylation of ERK was observed in the Ramp3
-/-
 cells (Figure 
7-2D), which was not consistent with our previous findings of increased basal pERK with 
GPR30/RAMP3 co-expression in HEK293 cells. Taken together, our experiments focused on 
the MAPK pathway suggest that constitutive signaling through GPR30 is likely occurring, as 
evidenced by the observed increase in basal ERK phosphorylation, but the role of RAMP3 in 
modulating this aspect of GPR30 function and the role of ligand stimulation remain unclear. 
Because GPR30 may also signal through the PI3K/AKT pathway [14], we performed 
western blot experiments similar to those described above but instead looking at 
phosphorylation of AKT. We did not observe any consistent effect on AKT activation with 
GPR30, with or without RAMP3, regardless of ligand treatment. Taking another approach to 
the signaling question in response to our inconclusive western blot experiments, we 
considered the fact that Frederik Leeb-Lundberg’s group has shown that GPR30 can recruit 
β-arrestin 2 [9]. Therefore, we utilized BRET assays to test whether we could reproduce this 
finding, and to determine whether this recruitment is altered by RAMP3. However, by this 
method we were unable to detect any recruitment of β-arrestin 2 to GPR30 with or without 
RAMP3, regardless of ligand treatment (G-1 or estrogen) (Figure 7-2E). Future attempts 
could utilize a confocal microscopy approach, similar to that used by the Leeb-Lundberg 
laboratory, to study β-arrestin 2 recruitment to the GPR30/RAMP3 complex. 
In vivo, we found that Ramp3
-/-
 hearts had reduced ERK phosphorylation compared to 
wildtype hearts (Figure 7-2F). However, without conclusive in vitro signaling studies to 
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complement this finding, we cannot directly determine whether this effect is due to changes 
in GPR30 signaling. We have previously shown that male, but not female RenTgMK;Ramp3
-
/-
 hearts have increased AKT phosphorylation compared to RenTgMK;Ramp3
+/+
 hearts [43]. 
Future studies could utilize remaining heart samples collected from our G-1 pellet studies 
[54] to determine whether downstream signaling through ERK or AKT is altered in vivo 
based on Ramp3 genotype, sex of the mice, or treatment condition. 
Furthermore, since GPR30 has been shown to elicit different downstream signaling 
pathways in different studies, and our own experiments have not yet yielded conclusive 
results, we could instead take a broad approach and utilize a high-throughput assay. This 
would allow us to systematically screen a variety of common GPCR downstream signaling 
pathways in response to GPR30-RAMP activation by either estrogen, aldosterone, or, as a 
positive-control, the synthetic agonist G-1. The Dual-Glo Luciferase Assay System from 
Promega is one such system that could be used, providing a sensitive screening format for 
determining G protein-coupled signaling pathways in luciferase reporter-based cell lines 
[55]. This assay would allow high-throughput screening for evaluating the effects of RAMPs 
on several modes of GPR30 signaling with several different ligands. However, the use of 
HEK293-based reporter cell lines does not necessarily provide a complete representation of 
these signaling pathways in physiologically-relevant cell types. Therefore, follow-up studies 
could be directed at validating the results from the luciferase screen in several “endogenous” 
cardiovascular cell lines such as cardiomyocytes (HL-1 cells), vascular smooth muscle cells, 
and human umbilical vein endothelial cells. Results from these studies would characterize the 
effects of RAMP-GPR30 interactions on ligand binding specificity and would determine how 
these interactions impact downstream signaling. 
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Future studies pertaining to GPR30/RAMP3 subcellular trafficking 
As previously discussed, RAMP3, but not RAMP1 or RAMP2, has been shown to 
interact with molecular chaperones to impact receptor recycling, and RAMP3 contains a PDZ 
domain in the C-terminus [41]. Interestingly, GPR30 contains a PDZ binding motif in its C-
terminus which is the mechanism by which GPR30 interacts with the scaffolding protein 
PSD-95 [10]. Therefore, interaction of GPR30 with other proteins, like RAMP3, through its 
PDZ binding motif is highly plausible. Furthermore, the PDZ domain of RAMP3 is 
important for another reason - it facilitates the interaction of RAMP3 with N-ethylmaleimide-
sensitive factor (NSF) [56]. NSF is a molecular component of the SNARE complex and its 
recruitment to early endosomal vesicles triggers rapid release of the endosome from the 
plasma membrane and subsequent recycling of endosomal cargo to the plasma membrane 
[57-59]. It has been demonstrated that PDZ-mediated association with NSF converts the 
canonical CLR/RAMP3 lifecycle from a degradative to a rapid recycling pathway, promoting 
rapid return of resensitized receptors to the plasma membrane [56]. An association of GPR30 
with RAMP3/NSF could help explain the differences in GPR30 subcellular localization 
observed in our studies and reported in the literature (modeled in Figure 7-3).  
To test this hypothesis, we could use our BRET-based receptor interaction assay as 
previously described. HEK293 cells would be transfected with hGPR30-RLuc alone, 
hRAMP3-YFP alone, or hGPR30-RLuc and hRAMP3-YFP together. For these studies, a 
time course experiment could be performed to compare the kinetics of the RAMP3/GPR30 
BRET signal with and without co-transfection of NSF, in the presence of the GPR30 ligand 
G-1. In addition, we could generate a RAMP3-RLuc construct with a mutation in the PDZ-
domain; similarly, cells could also be exposed to a pharmacological inhibitor of NSF, N-
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ethylmaleimide. We could then repeat the above experiment to determine whether the 
inhibitor treatment or RAMP3 PDZ mutation alters the time course or amplitude of the 
RAMP3/GPR30 BRET signal. 
Furthermore, to address the compartmentalization of GPR30/RAMP3/NSF complexes 
in live cells, future studies could make use of fluorescently tagged versions of GPR30 and/or 
RAMP3 and antibodies specific to early endosomal markers (EEA-1 proteins or rab5-GDP) 
in order to visualize in real-time the trafficking of RAMP3/GPR30 complexes by confocal 
microscopy. Association of the RAMP3/GPR30 complex with NSF may result in co-
localization with early endosomal markers and increased receptor levels at the plasma 
membrane. In contrast, inhibition of NSF, either through mutation of the RAMP3 PDZ 
domain or by pharmacologic inhibition, should result in increased receptor degradation and 
possibly localization to late endosomes (rab7-GTP). Together, results from these studies 
would help to clarify the details of how RAMP3 impacts GPR30 trafficking and subcellular 
localization. 
 
Future studies pertaining to pathophysiological significance of GPR30/RAMP interactions 
 In Chapter 6, we demonstrated that RAMP3 is required for the mediation of GPR30’s 
cardioprotective effects, and this effect is sex-dependent, as it was observed in male but not 
female mice. Future in vivo studies should aim to better understand the significance 
GPR30/RAMP3 interaction in cardiovascular disease, and to investigate potential in vivo 
roles for GPR30/RAMP1 and GPR30/RAMP2 interactions. 
We hypothesized that the reason the cardioprotective effects of GPR30/RAMP3 
activation were only observed in male mice could be because female mice have higher 
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endogenous levels of GPR30, RAMP3, as well as their endogenous ligand, estrogen. We 
therefore could substantially build on these findings by treating ovariectomized female mice 
with the GPR30 specific agonist, G-1, or placebo by the same method described in Chapter 6. 
The ovariectomized female mice would model the human post-menopausal state of low 
estrogen. Ovariectomized females may respond to G-1 in a similar fashion to males, and we 
expect this response to be RAMP3-dependent. These studies could help to clarify the 
potential relevance of the GPR30/RAMP3 pathway to heart disease in the human post-
menopausal state. 
Our studies have supported a RAMP3- and sex-dependent role for GPR30 in limiting 
cardiac hypertrophy. However, our published experiments terminated when the mice were 
approximately 14 weeks of age. Echocardiographic analysis of these mice, pre- and post-G-1 
treatment, did not reveal any significant differences in cardiac function, regardless of sex, 
genotype, or treatment condition (Figure 7-4A-D). This is not surprising, because we do not 
observe decreased cardiac function in our RenTgMK mice until approximately 5 months of 
age, and even then, only the RenTgMK;Ramp3
-/-
 males exhibit overt heart failure. To 
determine whether GPR30-mediated cardioprotection can slow or prevent the progression to 
heart failure, future studies could utilize transverse aortic constriction (TAC) to induce 
pressure-overload cardiovascular disease in Ramp3
+/+
 and Ramp3
-/-
 male and female mice. 
The same treatment regimen and phenotyping techniques utilized for the RenTgMK and 
RenTgMK:Ramp3
-/-
 mice could be performed, but the end point of the experiment could be 
extended to 6 months of age, when the mice will develop overload-induced heart failure. 
Based on our findings for cardiac hypertrophy, activation of GPR30 may attenuate the 
development of heart failure in the male Ramp3
+/+ 
mice challenged with TAC, but perhaps 
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not in the Ramp3
-/-
 or female mice. These experiments could determine whether 
pharmacological activation of GPR30 can prevent the transition to heart failure, and whether 
this depends on sex or RAMP3 genotype. 
The studies presented in this dissertation have so far focused on the interaction of 
RAMP3 with GPR30. However, because GPR30 can also interact with RAMP1 and RAMP2, 
RAMP3 may not be the only one with important effects on GPR30. Future studies could 
make use of the Caron Laboratory’s mouse models to test the effects of RAMP1 or RAMP2 
on GPR30 function in vivo. Ramp1
-/-
 mice are viable and fertile and do not exhibit overt 
disease phenotypes; Ramp2
-/- 
mice, however, are embryonic lethal. Ramp2
+/-
 mice survive 
but are haploinsufficient and thus have a profoundly reduced fertility and an expanded 
repertoire of endocrine related phenotypes. Thus, if future ligand binding and signaling 
studies reveal that RAMP1 or RAMP2 influence GPR30 activity, we could perform genetic 
crosses to generate RenTgMK;Ramp1
-/- 
and
 
RenTgMK;Ramp2
+/- 
mice. We could then 
implement the pharmacological treatment protocol and phenotyping described in Chapter 6 
to determine whether RAMP1 or RAMP2 have a role in GPR30-mediated cardioprotection in 
addition to the role we have already discovered for RAMP3. 
Our completed and future studies employ cell-based and genetic mouse models to 
elucidate the cellular and physiological consequences of GPR30/RAMP interactions. Our 
goal is to contribute in significant and novel ways to both the RAMP and GPR30 fields and 
to help catalyze entirely new areas of investigation. Our current and future results may help 
elucidate novel paradigms underlying sex-dependent differences of steroid hormone action in 
the heart, which may lead to novel therapeutic targets for gender-tailored treatment of 
cardiovascular disease.  
133 
 
FIGURES 
 
 
 
 
 
Figure 7-1. GPR30 interaction with RAMP1-3 
GPR30 interacts with RAMP1, RAMP2, and RAMP3, in vitro via bioluminescence 
resonance energy transfer. 
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Figure 7-2. GPR30/RAMP3 downstream signaling experiments 
A. GPR30 does not signal through cAMP, regardless of the presence of RAMP3. B. In 
transiently transfected HEK293 cells, GPR30/RAMP3 co-transfection increased basal ERK 
phosphorylation, but no ligand-specific response was observed. C. In HEK293 cells stably 
expressing GPR30 and transiently transfected with RAMP3, similar results were obtained. D. 
Mouse embryonic fibroblasts lacking RAMP3 showed increased basal ERK phosphorylation. 
E. Via BRET, GPR30 did not recruit β-arrestin 2 regardless of the presence of RAMP3. F. 
Ramp3
-/-
 hearts from adult mice have significantly reduced pERK compared to wildtype. 
Veh=vehicle, EV=empty vector, UT=untransfected.  
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Figure 7-3. Proposed model for GPR30/RAMP3/NSF complex recycling 
We hypothesize that interaction of NSF with RAMP3 will facilitate rapid recycling of the 
GPR30/RAMP3 complex back to the plasma membrane of the cell, resulting in 
resensitization of the receptor and maintenance of GPR30 signaling. Future studies will 
experimentally address this hypothesis. 
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Figure 7-4. Echocardiography data from G-1 treated RenTgMK Mice 
Selected echocardiography parameters from male and female RenTgMK;Ramp3
+/+
 and 
RenTgMK;Ramp3
-/- 
placebo or G-1 treated mice. A,C. Ejection fraction and B,D. Fractional 
shortening were not significantly different for male or female mice. Other parameters (not 
shown) were also not significantly different for either genotype or treatment condition. 
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